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ABSTRACT 
 
 
 Chronic inflammation has been identified as a major contributor to many diseases 
including, atherosclerosis, osteoporosis, dementia, Alzheimer’s disease and type 2 
diabetes, to name a few.  Many of the same markers of inflammation found in the 
diseases listed above, including IL-1, IL-6, TNF-α, NF-κB and adhesion molecules,  have 
also been found in wear debris induced osteolysis.  While the local response to 
biomaterial wear debris has been characterized quite extensively, very little is known 
about the systemic effect of biomaterial wear debris on the inflammatory system.  The 
objectives of this study were to evaluate the in vitro and in vivo inflammatory response to 
different biomaterial debris and to test the ability of the bisphosphonate, risedronate, in 
inhibiting the expected response. 
 In a co-culture of macrophages and endothelial cells, treated with commercially pure 
titanium (cpTi) particles and high density polyethylene (HDPE) particles, there were no 
significant increase in intracellular adhesion molecule-1 (ICAM-1).  Similarly, while not 
statistically significant, the addition of risedronate did lower the ICAM-1 values as 
compared to no treatment.   
 The second portion of this study was to assess the trajectory of biomaterial particles 
after being injected into the tail vein of the rat and to determine the effect of particle 
injection on ICAM-1.  Stainless steel (316L SS) and cpTi particles at a dose of 1 x 108 
particles per 24 hours were injected into the tail vein of the rat.  Two time points were 
studied: 24 hours after the first injection and 24 hours after the last of four injections (one 
injection per 24 hours) for a total exposure time of 96 hours.  After four injections, 
particles were observed in the spleens of all animals using light microscopy and the 
composition of the particles was confirmed using energy dispersive x-ray.  At 24 hours, 
there were no significant differences in ICAM-1 between SS, cpTi or the control groups.  
However, at 96 hours (or after four injections), the SS group exhibited a significantly 
higher ICAM-1 response than both the cpTi group and the control group.   
 For the final phase of this project, SS particles were injected into the tail vein of the 
rat and pro-inflammatory markers, IL-6, TNF-α, ICAM-1 and C-reactive protein (CRP) 
were measured to see if risedronate could inhibit the inflammatory response.  Three time 
points were analyzed: 1) 24 hours after one injection; 2) 96 hours after the fourth 
injections (one per day); and 3) 168 hours after the seventh injection.  Histology was 
performed and particles were found in all spleens after one injection of particles as well 
as after seven injections.  Particle injection elicited an increase in all measured 
parameters that varied over the course of duration.  While risedronate did not lower the 
cytokine response, IL-6 and TNF-α, it did lower the ICAM-1 response (after 168 hours) 
as well as the CRP response (after 24 hours). 
 This is the first study to describe the systemic inflammatory response to circulating 
biomaterial debris.  As seen in the local response, there was an increase in pro-
inflammatory cytokines as well as ICAM-1 and CRP.  The bisphosphonate, risedronate, 
inhibited the ICAM-1 and CRP response and thus may have a potential role in mediating 
wear debris induced osteolysis and inflammation.  Having a therapy that can not only 
prevent and treat bone loss, but may also inhibit chronic inflammation that may lead to 
atherosclerosis would be of significant importance. 
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PREFACE 
 
 
 
This study addresses the biocompatibility of biomaterials, with a focus on the effect 
of wear debris on systemic inflammation generated as a consequence of implant failure.  
The majority of data available on the adverse effect of biomaterial wear debris stems 
from the use of various materials in orthopaedics, specifically in total joint replacements 
(TJR).  This review will elaborate on the mechanisms of wear in TJR and the cellular 
response to the debris.  Additionally, the correlation with the inflammatory response from 
biomaterial wear debris and the vascular system will be explored, as well as a possible 
therapeutic intervention with bisphosphonates. 
 
Total joint replacements 
Sir John Charnley revolutionized total joint replacement in the early 1960’s and 
present day implants remain very similar to those used nearly 40 years ago.  Today, TJR 
is used to replace joints that are affected with degenerative diseases such as osteoarthritis 
or rheumatoid arthritis, and is one of the most successful surgical procedures in 
orthopaedics.  In 1995, 134,000 total hip replacements (THR) and 216,000 total knee 
replacements (TKR) were performed in the United States (National Center for Health 
Statistics, 1995).  By 2001, the number of total hip and knee replacements performed had 
increased to 165,000 and 326,000, respectively (National Center for Health Statistics, 
2001).  More recent data show that from 1995 through 2004 in patients 65 years and 
older, the rate of hip replacements increased 38 percent and the rate of knee replacements 
increased 70 percent (DeFrances and Podgornik, 2006).  As the baby boomers age and 
the general population enjoy a more active lifestyle, the number of TJRs is likely to 
increase significantly over the next several years. 
The majority of total joint replacements consist of a metallic component, either a 
cobalt chromium alloy (CoCr) or a titanium (Ti) alloy, articulating against ultra high 
molecular weight polyethylene (UHMWPE).  In normal, healthy joints, the viscous 
synovial fluid separates the cartilage surfaces and the joints function under low friction 
and almost no wear.  In diseased joints, the synovial fluid loses its viscosity and its ability 
to allow the joint to operate under low friction and wear.  In the situation where the 
diseased joint has been replaced with artificial components, the surfaces of the two 
implants come into contact with each other and wear particles are produced.   
Primarily, the wear particles are generated from the articulating surfaces of the 
implant and then enter the periprosthetic tissues where they are phagocytized by 
macrophages (Ingham and Fisher, 2005).  The macrophages then release a variety of pro-
inflammatory cytokines and other mediators of inflammation that eventually leads to 
osteoclast activation, periprosthetic osteolysis and loosening of the implant.  It is 
estimated that twenty percent of the total joint replacements performed each year in the 
United States will have periprosthetic osteolysis and loosening within 10 years (Jacobs et 
al., 1994; Maloney et al., 1990; Martell et al., 1993).  While loosening of the implant is a 
major concern and preventing this complication is of much interest, little is know about 
what effect the biomaterial particles may have systemically.  Additionally, while the 
majority of the data available comes from the study of total joint replacements, 
biomaterial particles may also be generated from other types of implants.  The 
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mechanisms of particle generation can vary and will be discussed next.  The effects of 
biomaterial wear debris will be discussed in more detail in the later sections. 
 
Mechanisms of Wear 
Due to poor lubrication protection in the artificial joint, the two surfaces rub against 
each other leading to wear.  Wear is defined as the removal of material from a bearing 
surface.  There are numerous factors that influence the wear behavior of implants: overall 
implant design, polyethylene thickness, surface finish of articulating bearings, implant 
alignment, patient activity or weight and physiochemical properties of the polyethylene 
(Hirakawa et al., 1996).  There are four main types of wear: adhesive, abrasive, third-
body wear, and corrosion and surface fatigue (Savio et al., 1994).  While technically not 
classified as a wear mechanism, surface fatigue of materials does take place and particles 
are released in the surrounding area.  Therefore, for this study, surface fatigue will be 
included in the wear section.  
 
Adhesive Wear 
 Adhesive wear occurs when a local contact is present between two surfaces and 
on subsequent movement the contact is broken.  The particle is either released or 
transferred from one surface to the other.  In the case of total joint replacements, this 
type of wear usually manifests in a thin film of UHMWPE being transferred to the 
metal counterpart. 
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Abrasive Wear 
 Abrasive wear occurs when asperities on the harder material (the metallic 
component) cut or plough into the softer material (UHMWPE).  When orthopaedic 
companies manufacture implants, great efforts are made to attempt the removal of 
any asperities on the surface of the implant.  However, due to poor lubrication 
conditions in TJRs, the surfaces come into contact with each other and even the 
smallest of asperities (nanoscale) lead to abrasive wear. 
 
Third-Body Wear 
 When wear particles, generated from other wear mechanisms, become trapped 
between the bearing surfaces, third-body wear occurs.  The particles will act directly 
on one or both of the surfaces, depending on their relative hardness, to exacerbate the 
wear process (Sedel, 1992).  It is also possible for these particles to become 
embedded in polymeric surfaces and score the harder counterfaces (Black et al., 
1990).  Third-body wear in TJRs would occur when polymethylmethacrylate 
(PMMA) fragments or metal particles from porous coatings become trapped between 
the bearing surfaces, leading to wear. 
 
Corrosion and Surface Fatigue 
 Corrosive wear occurs in the presence of a hostile environment, such as the 
human body.  In this situation, the products of corrosion (the passivation layer) are 
continuously worn away by sliding action so that corrosion can progress.  Fretting is 
often associated with corrosion and can be found in total hip replacements between 
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the acetabular shell and a fixation screw, at the Morse taper junction of the femoral 
component of modular hip implants, and at the stem-cement or bone-cement 
interface.  Fretting is also commonly found in fracture fixation devices where screws 
come into contact with plates, for example. 
 The essential feature of this type of wear is varying stress where elements of the 
material on or just under the surface are cyclically stretched, compressed or sheared 
until the fatigue limit of the material is exceeded.  The higher the stresses and the 
more cycles of load, the greater the amounts of fatigue wear.  Due to the concentrated 
cycle loading on the surface, surface and subsurface cracks are formed which can lead 
to surface break-up and the release of large fragments of material.  Delamination can 
be classified under fatigue wear. 
 
Regardless of the type of wear mechanism that occurs, the fact remains that wear 
particles are produced.  In machinery, the greatest concern would be over mechanical 
failure of the tribosystem.  However, in total joint replacements, the major present 
concern is the contribution of these particles to the biological demise of the joint 
replacement. 
 
TJR wear debris 
 The two major types of wear debris that have been identified and studied are 
polyethylene wear particles and metal wear particles.  Interestingly, in bulk, these 
materials are relatively inert and provoke a non-immunologic foreign body response.  
However, the materials become a threat to the life of the implant when they are present in 
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very small sizes where macrophages can ingest the debris and release cytokines that lead 
to bone resorption.  Retrieval studies have demonstrated that the majority of ultra high 
molecular weight polyethylene and metallic particles found in tissues were less than 1-3 
microns (Shanbhag et al., 2000; Maloney et al., 1995; Campbell et al., 1996).  Particle 
size is very important as studies have clearly demonstrated that the most biologically 
active size range of particles is 0.1-1.0 microns (Green et al., 1998; Matthews et al., 
2000). 
 There is a preponderance of evidence to suggest that cellular interaction with implant 
debris can lead to the release of powerful osteolytic factors that are generally located in 
the osseous microenvironment (Attawia et al., 1999).  From previous studies, it appears 
that osteolysis is a result of macrophage activation secondary to the phagocytosis of 
particulate wear debris, and has been associated with metallic debris (Buly et al., 1992; 
Nasser et al., 1989; Nasser et al., 1990; Horowitz et al., 1998; Trindade et al., 2001; 
Brown et al., 2006) and polymeric debris (Kilgus et al., 1992; Santavirta et al., 1990; 
Schmalzried et al., 1992; Matthews et al., 2001). Many materials, such as cobalt, 
titanium, polyethylene, and polymethylmethacrylate have been shown to activate 
macrophages to secrete cytokines associated with bone resorption (Gonzales et al., 1996; 
Haynes et al., 1993; Horowitz and Purdon, 1995; Pacific, 1995).  When small particles 
are present in sufficient numbers, phagocytosis can result in the activation of 
macrophages and in the direct resorption of the bone by macrophages (Adams and 
Hamilton, 1984; Athanasou et al., 1992; Holtrop et al., 1982; Mundy et al., 1977; Murray 
and Rushton, 1990; Santavirta et al., 1992).  In the case of TJRs, billions of particles of 
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wear debris are generated each year by and become embedded in the surrounding tissue, 
where as many as 109 particles per gram of tissue have been identified (Margevicius et 
al., 1994).  These particles initiate an inflammatory response whereby small particles (< 
10 μm) are phagocytosed and stimulate the release of inflammatory cytokines, including 
tumor necrosis factor-α (TNF-α), interleukin (IL)-1, and IL-6, which have been linked to 
bone resorption (Friedman et al., 1994; Horowitz et al., 1993).  The following sections 
will provide a more in depth analysis of the biological response to wear debris. 
 
Biological responses to biomaterial wear debris 
 The cells within the interface tissue produce many pro-inflammatory factors that are 
implicated in periprosthetic bone and soft tissue remodeling and osteolysis.  These factors 
include numerous cytokines, chemokines, prostanoids, superoxide anions, nitric oxide 
metabolites, lysosomal enzymes, metalloproteinases, and adhesion molecules (Al-Saffar 
et al., 1995; Boynton et al., 1995; Chiba et al., 1994; Goodman et al., 1989; Goodman et 
al., 1997; Goodman et al., 1996; Horikoshi et al., 1994; Ishiguro et al., 1996; Jiranek et 
al., 1993; Kim et al., 1994; Konttinen et al., 1997; Ohlin et al., 1990; Sabokbar and 
Rushton, 1995; Santavirta et al., 1993; Takagi et al., 1994; Takagi et al., 1994; Takagi et 
al., 1995; Takagi et al., 1995; Watkins et al., 1997; Xu et al., 1996; Xu et al., 1997).  Of 
particular interest to this study was the identification of cytokines and adhesion 
molecules. 
 Cytokines are short-lived proteins that have effects at extremely low concentrations; 
cytokines act locally to modulate numerous cellular processes including growth, 
differentiation, and maturation of cells (Goodman et al., 1998).  The cytokines that 
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generally have been associated with osteolysis include: tumor necrosis factor α (TNFα), 
interleukin 1 (IL-1), IL-6, and platelet derived growth factor.  In a study of retrieved 
interface (periprosthetic) membranes, Chiba and coworkers (1994) showed that 
membranes from patients with failed total hip replacements, both with and without 
evidence of osteolysis, released significantly higher levels of IL-6, collagenase, 
prostaglandin E2 (PGE2), IL-1, and TNF-α into culture media than did control 
membranes.  Additionally, IL-1, IL-6 and TNF-α activity levels in the group with 
osteolysis were significantly higher than in the group without osteolysis, although the 
activity of IL-1 and TNF-α was much lower than that of IL-6.  Recently, Stea and 
coworkers (2000) conducted an analysis of retrieved tissues around failed total hip 
prostheses and found that the percentage of cells positive to IL-1, IL-6 and particularly to 
TNF-α increased in relation to the tissues collected at the interface of stable components.  
Also, another study looked at retrieved synovial tissue and fluid samples from patients 
undergoing primary and revision total hip and total knee replacements (Clarke et al., 
2001).  They found that all cytokine levels were higher in revision TJRs than in primary 
replacements, as were the degree of macrophage and giant cell infiltration.  Other studies 
have also established the expression in interface membranes of IL-1, TNF-α, and PGE2 
which are strongly implicated in the induction and maintenance of bone resorption 
(Jiranek et al., 1993; Al Saffar and Revell, 1994; Sedel et al., 1992; Konttinen et al., 
1996; Campbell et al., 1996).    
 In addition to studies of the surrounding membranes, cell culture studies have also 
been conducted to determine the isolated effect of biomaterial particles on the 
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inflammatory response.  While the techniques have varied from study to study, most of 
the cell culture experiments have confirmed the ability of isolated human and murine 
macrophages to secrete IL-1, IL-6, TNF-α and PGE2 in the presence of different wear 
particles, including: polymethylmethacrylate (PMMA), UHMWPE, high density 
polyethylene (HDPE), commercially pure titanium (cpTi), Ti6AL4V (retrieved and 
fabricated), Co-Cr (retrieved and fabricated) and stainless steel (Murray and Rushton, 
1990; Westacott et al., 1992; Shanbhag et al., 1995; Algan et al., 1996; Sun et al., 1996; 
Lee et al., 1997; Haynes et al., 1998; Nakashima et al., 1999; Robinson et al., 1999, Xing 
et al., 1999).  In fact, it has been shown in cell culture that the most biologically active 
debris is submicron in size and larger particles elicit little cytokine response (Shanbhag et 
al., 1994; Matthews et al., 2000; Green et al., 2000).  The number of particles tested in 
culture varied greatly, which is understandable since it is difficult to know how many 
particles are generated in vivo at any given time.  However, several studies demonstrated 
that the larger the particle volume to cell number ration, the greater the cytokine response 
(Haynes et al., 1998; Pollice et al., 1998; Matthews et al., 2000).  Interestingly, it has also 
been shown that phagocytosis of titanium particles by macrophages may not be necessary 
for release of IL-6 and TNF-α (Nakashima et al., 1999, Soloviev et al., 2005).  It is 
proposed that the particle interaction with the cell membrane led to the increase in IL-6 
and TNF-α. 
 Sun and coworkers (1996) also evaluated whether or not serum played a role in the 
activation of cytokines.  They tested both particles free of protein and particles coated in 
serum and found that particulate debris free of serum protein was a sufficient stimulus for 
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macrophage activation.  Thus, the particles themselves may serve as the active factor in 
the loosening process in TJR.  The concept of particle only induction of cytokines has 
been further studied by taking into account adherent endotoxin on the debris.  In six 
known studies, using different types of wear debris and measuring a variety of biological 
responses, it has been shown that adherent endotoxin is an important stimulator of wear-
particle induced osteolysis (Ragab et al., 1998; Cho and Goldring, 1999; Daniels et al., 
2000; Hitchins and Merritt, 1999; Akisue et al., 2000; Aspenberg, 2000).  Endotoxin can 
be found on particles used for tests such as in commercially pure titanium (Ti) particles 
and on discs of Ti or Ti6Al4V that have been prepared, processed, and packaged by a 
major manufacturer of orthopaedic implants exactly as they prepare, process, and 
package actual implants (Ragab et al., 1999).  Therefore, one source of endotoxin on 
orthopaedic wear particles is likely to be the implants themselves.  While the above 
studies have indicated that the cytokine response seen after challenge with debris is 
dependent of adhered endotoxin, a study by Pollice and coworkers (1998) found a 
significant cytokine response in the absence of adherent endotoxin.  Also, Tatro and 
colleagues (2007) found that there is a balance between endotoxin accumulation and 
endotoxin clearance and this controls the steady state level of endotoxin surrounding 
biomaterial wear particles.  Thus, the balance may regulate the rate of osteolysis in 
animal studies as well as in patients with aseptic loosening. 
 Although macrophages are the predominant cell type in tissues surrounding loose 
prostheses, complex interactions between macrophages, fibroblasts, osteoblasts, 
osteoclasts, and other cells have been described (Horowitz et al., 1994).  Many of the 
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inflammatory factors and immune modulators listed above have direct or indirect effects 
on the differentiation and maturation of osteoclasts, and facilitate overall osteoclast 
function (Goodman et al., 1998).  IL-1 and TNF-α induce not only the production of IL-6 
by macrophages, fibroblasts, and endothelial cells, but also the proliferation of fibroblasts 
and endothelial cells and are stimulators of osteoclastic bone resorption (Gowen et al., 
1983; Sherry and Cerami, 1988).  In 1990, it was found that IL-6 directly induces 
osteoclastic bone resorption (Ishimi et al., 1990; Kurihara et al., 1990).  Biochemical and 
immunohistochemical results suggest that macrophages, fibroblasts, and endothelial cells 
in the membranes react with metal and/or polyethylene debris and produce IL-6, which 
directly stimulates osteoclasts in patients with focal osteolysis (Chiba et al., 1994).  Since 
IL-1 and TNF-α both stimulate osteoclastic bone resorption and induce IL-6 (Heinrich et 
al., 1990; Helle et al., 1988; Ishimi et al., 1990), another possibility is that IL-1 and TNF-
α may contribute to the osteoclastic bone resorption directly as well as indirectly through 
the induction of IL-6 production by macrophages, fibroblasts, and endothelial cells 
(Chiba et al., 1994).   
 In another study, PGE2, IL-6, and IL-8, and adhesion molecules (soluble intercellular 
adhesion molecule, soluble vascular adhesion molecule, and soluble endothelial 
leukocyte adhesion molecule) were elevated significantly in joint fluid of patients with a 
loose hip prosthesis, compared with controls undergoing primary total hip replacement 
(Sabokbar and Rushton, 1995).  In 1995, Al-Saffar and coworkers characterized the 
cellular interactions and the mechanisms involved in the recruitment of inflammatory 
macrophages to the bone implant interface in patients with aseptically loosened 
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prostheses.  The study described the histological pattern of vascular growth and 
demonstrated the induction and upregulation of three types of adhesion molecules in the 
bone-implant interface: endothelial leukocyte adhesion molecule-1 (E-selectin); 
intercellular adhesion molecule-1 (ICAM-1); and vascular cell adhesion molecule-1 
(VCAM-1).   
 There may also be some specificity with regard to the mediator profile when 
macrophages are exposed to different types of particles generated from various 
biomaterials.  Horowitz and Gonzales (1997) found that murine macrophages exposed to 
high density polyethylene (HDPE) expressed increased amounts of TNF-α and PGE2 as 
compared to controls but the increase was not statistically significant and IL-1β was not 
detected.  However, when they tested the effect of HDPE on a co-culture of macrophages 
and osteoblasts, there was a twenty times greater production of PGE2 and increased IL-6. 
Different responses to biomaterial debris was also noted by Shanbhag and coworkers 
(1995), which showed that human monocytes exposed to retrieved and fabricated 
UHMWPE released PGE2, similar to the study by Horowitz and Gonzales, but unlike the 
Horowitz study, there was also a presence of IL-1β and IL-6 under certain conditions.  In 
fact, there were differences in cytokine release between cells exposed to retrieved PE 
particles and those exposed to fabricated PE particles, indicating once more that the types 
of cells or particles used may lead to different results. 
 As indicated above, the cytokine response in co-culture was different than when 
macrophages alone were exposed to HDPE.  Co-cultures are used to assess 
biocompatibility of orthopaedic biomaterials in the presence of two different cell types 
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and thus allow an interactive response between the two types of cells.  Similar results 
have also been demonstrated with murine macrophages exposed to 
polymethylmethacrylate, where there was a significant increase in PGE2 in the co-culture 
system over the cells by themselves (Attawia et al., 1999).  These results indicate that 
previous studies that evaluated only one cell type may have underestimated the effect of 
wear debris on the production of pro-inflammatory cytokines and thus the bone 
resorption potential of implant debris particles in the clinical mechanism of aseptic 
prosthetic loosening (Attawia et al., 1999). 
 
Systemic distribution of wear debris 
  As shown in the previous sections, there are numerous studies analyzing the effects 
of particulate debris on the surrounding tissues or on cells within cell cultures, however, 
relatively little is known concerning the dissemination of wear debris beyond the local 
tissues.  In fact, the nature and ultimate fate of wear and corrosion products generated by 
joint replacement prostheses and the implications of long-term systemic exposure to these 
products are among the least understood aspects of arthroplasty of the hip or knee (Urban 
et al., 2000).  There are, however, several studies that have looked at the systemic 
distribution of debris and these studies will be discussed further. 
 Several studies have found elevated levels of metallic elements, same as those that are 
used to make orthopaedic implants, in distant organs and body fluids of patients with 
total joint replacements (Bartolozzi and Black, 1985; Jacobs et al., 1991; Jacobs et al., 
1995; Jacobs et al., 1996; Kreibich et al., 1996; Jacobs et al., 1998; Jacobs et al., 1999).  
However, the quantities of the elements have not been elucidated nor their location within 
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the organs (Urban et al., 2000).  Several other small case reports of systemic wear debris 
are mostly related to infiltration of regional lymph nodes by particulate debris (Bae et al., 
1996; Basle et al., 1996; Dudorkinova et al., 1997; Gray et al., 1989; Hicks et al., 1996).  
In 1996, Basle and coworkers harvested lymph nodes in nine patients who had either 
THR or TKR and were undergoing surgical treatment for pelvic carcinoma (five cases) 
and for isolated pseudomalignant lymphadenopathy (four cases).  They found both metal 
and polyethylene particles in histiocytes within the lymph nodes.  However, the metallic 
particles were only found to be abundant in two cases while polyethylene particles were 
abundant in all cases.  The authors concluded that the migration of polyethylene debris 
from the prosthetic site seems to be the major factor in development of the histiocytes 
induced in satellite lymph nodes (Basle et al., 1996).  Similar results have also been 
found by Hicks and colleagues (1996), where they found polyethylene or metal debris in 
all lymph nodes harvested from five patients who had a total of eleven arthroplasties in 
seven hips and who were undergoing a pelvic staging procedure for adenocarcinoma (of 
the prostate in four patients and of the endometrium in one).  Additionally, expression of 
IL-1β, IL-6 and TNF-α was increased in the involved lymph nodes. 
 Particles, thought to be generated by prostheses, have also been found in distant 
organs, including the liver, spleen, bone marrow and lymph nodes in a small number of 
patients (Case et al., 1994; Langkamer et al., 1992; Engh et al., 1997; Peoc’h et al., 
1996).  The highest concentrations of particles have been found in the bone marrow and 
lymph nodes (Case et al., 1994), indicating the systemic distribution of orthopaedic wear 
particles.   
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 The largest study analyzing the systemic distribution of wear particles was conducted 
by Urban and coworkers in 2000.  In this study, postmortem specimens from twenty-nine 
patients who had had a hip or knee replacement were compared to postmortem specimens 
from fifteen patients who had not had an orthopaedic implant.  Also, biopsies from two 
living patients with failed implants were studied.  The objective of this study was to 
determine the prevalence of, and the histopathological response to, prosthetic wear debris 
in specimens of liver, spleen, and distant lymph nodes.  This study showed that the 
dissemination of wear particles to the liver, spleen, or abdominal lymph nodes is a 
common occurrence in patients with a total hip or knee replacement.  Metallic or 
polyethylene wear particles were present in the para-aortic lymph nodes of eighty-nine 
percent (twenty-five of twenty-eight) of the patients with a TJR from whom lymph nodes 
were available for study.  When analyzed individually, metallic particles were found in 
sixty-eight percent (nineteen of twenty-eight) of the para-aortic lymph nodes from 
patients who had had a TJR.  Likewise, polyethylene particles were found in sixty-eight 
percent (nineteen of twenty-eight) of the lymph nodes from patients who had had a TJR.  
Additionally, metallic or polyethylene wear particles were more prevalent in the liver and 
spleen in patients who had had a previously failed TJR (seven of eight) than in patients 
who had had a primary hip (three of eleven) or knee (three of ten) replacement.  Metallic 
particles were identified in thirty-eight percent (eleven of twenty-nine) and polyethylene 
particles in fourteen percent (four of twenty-nine) of the specimens from the liver or 
spleen in patients who had TJR.  The concentration of wear particles in the liver and 
spleen were relatively low in the majority of patients, however, in the two living patients 
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who had a failed implant, the concentrations of particles were very high in the liver and 
spleen.  Interestingly, when the metallic particles found in the liver and spleen were 
analyzed it was found that the particles were generated from non-bearing surfaces of the 
implant, and not the primary bearing surface.  The majority of the debris identified was 
less than one micron and since current methods lack the sensitivity and specificity to 
detect very low concentrations of submicron polyethylene in tissues, it is reasonable that 
the prevalence of polyethylene debris in the liver and spleen was underestimated (Urban 
et al., 2000). 
 The above studies have clearly demonstrated the presence of orthopaedic wear debris 
in the liver, spleen and lymph nodes of patients with failed prostheses; however the 
mechanism of transport has not been clearly elucidated and may be a combination of 
several factors.  Urban and colleagues suggested that lymphatic transport was a major 
route for dissemination for wear debris in the above study (Urban et al., 2000).  The 
particles may have traveled through perivascular lymph channels as free particles or as 
phagocytized particles within macrophages (Harmsen et al., 1985).  In the liver and 
spleen, the smaller particles were in mobile macrophages of the portal tracts of the liver, 
most likely by means of lymphatic transport (Urban et al., 2000).  For those patients who 
had extensive dissemination of debris, the particles were also found in the fixed 
macrophages of Kupffer cells lining the hepatic sinusoids, suggesting the possibility of 
hematogenous dissemination as well as lymphatic (Urban et al., 2000).  Al-Saffar and 
colleagues (1995) also suggested that the presence of metal wear debris in the serum of 
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patients with failed prostheses would be the result of the release of debris-containing 
phagocytes into the circulation. 
 Particles may also be transported to and found in sites that were not studied by Urban 
and coworkers.  It has been hypothesized that particles may be transported to remote 
bone marrow by circulating monocytes or by entry of small particles directly into the 
bloodstream (Engh et al., 1997).  Additionally, Simonian and Robinson (1995) have 
reported that titanium wear debris was found in blood that was cycled through an 
interoperative blood-conservation system used during revision of a THR.  This finding 
may also indicate that microscopic metallic particles may be directly infused into the 
bloodstream. 
 
Wear particles from biomaterials other than TJR 
 All of the above studies have focused on debris generated from total joint 
replacements.  However, wear debris may be generated from different types of 
biomaterial implants besides TJRs.  For example, a one year study of medial collateral 
ligament replacements in sheep showed that wear debris was found in thirty-three percent 
of the lymph nodes tested (inguinal, iliac and para-aortic) and in at least one node in 
eighty-four percent of all sheep (Margevicius et al., 1996).  In addition, metallic debris 
has also been found in the paraspinal soft tissues of patients with titanium spinal implants 
(Wang et al., 1999).  It was determined that the wear debris was generated by pedicle 
screw constructs and deposited in the soft tissue surrounding the implant.  A macrophage 
cellular response was also noted with phagocytosis of the metal particles.  This study did 
not analyze systemic distribution of the titanium wear debris but as with TJRs the 
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possibility exists that the debris may be transported elsewhere within the body.  Lastly, it 
is possible that debris from aortic stent graft devices may be generated by failure of these 
devices and that this debris may enter the circulation.  Jacobs and colleagues (2003) 
evaluated the mechanical failure of prosthetic human aortic stent grafts over a ten-year 
period.  A total of six hundred eight-six endovascular stent grafts were used to treat 
patients with aortic aneurysms and sixty patients were identified with device fatigue.  Of 
the sixty failures, forty-three had metallic stent fractures, fourteen had suture disruptions 
and three had holes in the grafts.  Interestingly, these material failures occurred within 
seven distinct stent graft designs and the mean time to failure was nineteen months.  
According to Jacobs, the clinical significance of stent graft material failure remains 
uncertain but as shown in the previous sections, the material, if released, may be 
transported to other sites in the body and may invoke an inflammatory response. 
 
Local vascular response to wear debris 
 Based on an extensive literature search, four studies were found that looked at the 
local vascular response to particulate debris.  The first study characterized the cellular 
interactions and the mechanisms involved in the recruitment of macrophages to the bone 
implant interface (Al-Saffar et al., 1995).  While it is known that these cells are present in 
the interface of failed prostheses, what is not known for certain is the mechanism 
responsible for the entry and accumulation of these cells in the bone-implant interface.  
However, it is thought that the process of neovascularization and the activation of 
vascular endothelium may play a significant role.  The goal of this study was to 
investigate the possible role of different types of wear debris in the induction of vascular 
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endothelial adhesion molecules on different cells in the bone-implant interface, and to 
assess their role in the initiation of the cellular inflammatory response in those 
membranes (Al-Saffar et al., 1995).  In this study, thirty patients with aseptically 
loosened implants were evaluated, nineteen of the patients had total hip replacements and 
eleven had total knee replacements.  The results from this study demonstrated the 
induction and upregulation of ICAM-1, VCAM-1 and E-selectin (ELAM-1) in the bone-
implant interface.  These findings support the clinical observation of the presence of a 
local chronic inflammatory response in the interface and the contribution of wear debris 
in the induction of this response.  In fact, the level of expression of adhesion molecules in 
the failed tissues was comparable to the levels found in inflammatory joint conditions.  
Al-Saffar and colleagues also postulated that the increased expression of the three 
adhesion molecules was mediated by the local production of IL-1 and TNF-α in the 
failed tissues. 
 The second study measured concentrations of pro-inflammatory cytokines and 
soluble adhesion molecules in the hip joint synovial fluid of twelve patients undergoing 
primary total hip arthroplasty and eight patients undergoing revision total hip arthroplasty 
(Sabokbar and Rushton, 1995).  The results from this study demonstrated a significant 
increase in the cytokines PGE2, IL-6 and IL-8 and the soluble adhesion molecules ICAM-
1, VCAM-1 and E-selectin.  Based on the author’s conclusions, these results suggested 
that synovial fluid and its inflammatory contents might play a significant role in aseptic 
loosening of total hip arthroplasties (Sabokbar and Rushton, 1995).  
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 The third study evaluated the response of capillaries and postcapillary venules of 
striated muscle to submicron particles of stainless steel or commercially pure titanium 
(Kraft et al., 2001).  The microvascular response was quantitatively measured for 
leukocyte-endothelium interaction, leukocyte extravasation (indicative of adhesion 
molecule activation), macromolecular extravasation (as an indicator of the endothelial 
integrity) and perfusion.  The results from this study indicated that wear particles led to 
the activation of leukocytes with a notable increase in the leukocyte endothelial-cell 
interaction within the first 120 minutes and peaked from the 8-24 hour range.  Stainless 
steel particles elicited a greater response than did the titanium particles, with a far more 
negative effect on virtually all microcirculatory parameters.  The authors concluded that 
not only does wear debris induce a chronic biological reaction but also a marked acute 
tissue response with significant effects to the microcirculation (Kraft et al., 2001).   
 The last study evaluated the effects of 316L stainless steel (SS) on human umbilical 
vein endothelial cells (HUVEC).  Martinesi and colleagues (2007) demonstrated that 
exposure of the HUVEC to SS elicited TNF-α, IL-6 and TGF-β responses, as well as 
increases in ICAM-1, VCAM-1 and E-selectin. 
 
Potential impact of biomaterials on chronic inflammation 
 As described above, there are various pro-inflammatory cytokines and adhesion 
molecules that are released in the presence of biomaterial wear debris.  Whereas the local 
response to biomaterial debris has been studied extensively, little is known about the 
systemic effect of biomaterial debris that may be disseminated throughout the body.  
Where it may have an effect that has not been previously analyzed is on the possible 
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contribution to chronic disease.  Chronic inflammation appears to be involved in the 
pathogenesis of age-related diseases such as: atherosclerosis, peripheral vascular disease, 
coronary artery disease, osteoporosis, Type 2 diabetes, dementia and Alzheimer’s disease 
and some forms of arthritis and cancer (Omoigui, 2007; Chung et al., 2006; Vasto et al., 
2007; Payne, 2006).  Some of the key contributors to the inflammatory process are the 
age-related upregulation of NF-κB, IL-1β, IL-6, TNF-α, cyclooxygenase-2, adhesion 
molecules and inducible NO synthase (Chung et al., 2006).  Elevated levels of CRP, IL-6 
and TNF-α have been associated with an increased risk of cardiovascular disease 
(Morrow and Ridker, 2000; Cesari et al., 2003).  Also, increased levels of pro-
inflammatory cytokines have been positively correlated with risk of primary and 
recurrent myocardial infarction and death (Ridker et al., 2000; Ridker et al., 2000).  There 
is also evidence for a possible role of inflammation in Type 2 Diabetes where increased 
levels of CRP and IL-6 predict the development of this disease (Omoigui, 2007).  IL-6 
levels are also higher in inflammatory joint disease (Kotake et al., 1996) and in 
conditions of rapid bone turnover and hypercalcemia as in Paget’s disease and multiple 
myeloma (Roodman, 1995).  In postmenopausal women, a direct correlation has been 
shown between bone resorption and serum IL-1, IL-6 and TNF-α levels where the 
identified cytokines stimulate osteoclasts (Miyaura et al., 1995).  Cytokines also induce 
the expression of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1) on endothelial cells that leads to the subsequent increased 
adhesion of monocytes and is involved in the pathogenesis of atherosclerosis (Takahashi 
et al., 1996; McFarlane et al., 2004). 
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 Chronic inflammation from one disease state, such as those listed previously, may 
also increase a patient’s risk of developing another disease.  For example, patients with 
prolonged rheumatoid arthritis (RA) have a higher incidence of atherosclerosis than 
patients of the same age with more recent disease onset (del Rincón et al., 2006).  The 
additional inflammatory insult by chronic diseases appears to accelerate atherosclerosis 
and its complications and may be an explanation for higher cardiovascular morbidity and 
mortality in these populations (Tsirpanlis, 2005).  There is also emerging evidence of a 
biological link between osteoporosis and atherosclerosis and the correlation has been 
described in more detail elsewhere (Hamerman, 2005; Danilevicius et al, 2007; 
Bevilacqua et al., 2005; Ylitalo, 2002).  In atherosclerosis, inflammatory cytokines, such 
as IL-1, IL-6 and TNF-α, are released by smooth muscle cells, endothelium and 
macrophages.  Cytokines induce the expression of intracellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells that 
leads to the subsequent increased adhesion of monocytes and is involved in the 
pathogenesis of atherosclerosis (Takahashi et al., 1996; McFarlane et al., 2004).  Finally, 
macrophages and monocytes cause the differentiation of cells in the vessel wall leading 
to calcification (Tintut et al., 2002).  In osteoporosis, inflammatory cytokines lead to the 
activation of osteoclasts and subsequent bone resorption.  Clinically, risk factors for 
vascular disease, such as dyslipidemia, systemic arterial hypertension, diabetes mellitus, 
and hyperhomocystinemia, have been associated with a higher incidence of low-bone 
mineral bone density (Danilevicius et al., 2007).  And, there are many similarities 
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between arterial calcification and osteogenesis, including various cells, proteins and 
cytokines that lead to tissue mineralization (McFarlane et al., 2004).   
 Since chronic inflammation is a factor in many diseases, it appears that a chronic 
inflammatory state may increase the risk of developing other diseases over time.  Thus, it 
would be prudent to identify causes of chronic inflammation that have the potential to be 
modifiable so as not to predispose patients to a potential increased risk of developing 
inflammatory mediated diseases.   
 
Commonality between bone disease and atherosclerosis 
 As mentioned above, inflammation is involved in the pathogenesis of both 
atherosclerosis and osteoporosis.  Both diseases account for significant morbidity and 
mortality and are independent predictors of cardiovascular disease (Stafford et al., 2004; 
Kado et al., 2000; Jorgensen et al., 2001).  Data also suggest an inverse relationship 
between bone density and calcified atherosclerosis.  Atherosclerosis is characterized by 
the accumulation of lipid material in the arterial wall resulting from autoimmune and 
inflammatory mechanisms (Libby et al., 2002) and more than 90% of these fatty plaques 
undergo calcification (Tintut and Demer, 2001).  Whereas oxidized low-density 
lipoprotein cholesterol is known to promote arterial calcification, it actually inhibits 
calcification of bone (Parhami et al., 1997). 
 Local and serum lymphocytes, monocytes and macrophages play an important role in 
osteoporosis and vascular calcification (Danilevicius et al., 2007).  Most inflammatory 
cytokines, such as IL-1, TNF-α and IL-6 are produced in the vascular wall by the 
endothelium, smooth muscle cells and macrophages.  These cytokines increase the 
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expression of adhesion molecules on leukocytes and endothelial cells (P-selectin and 
ICAM-1), in addition to stimulating the transcription of genes responsible for the 
production of chemotactic factors (McFarlane et al., 2004).  Macrophages and 
monocytes, which are frequently found in atherosclerotic plaques, induce the osteogenic 
differentiation of cells in the vessel wall, provoking vascular calcification (Tintut et al., 
2002).   
 Inflammatory cytokines also play a role in osteoporosis where they are potent 
promoters of bone resorption through osteoclast activation.  Bone resorption was found to 
be directly correlated with serum IL-1, IL-6 and TNF-α levels in post-menopausal 
women, and this action was inhibited by anti-TNF-α and anti-IL-1 antibodies (McFarlane 
et al., 2004).  Additionally, these cytokines also lead to the proliferation and 
differentiation of osteoclast precursors (Miyaura et al. 1995).   
 There are additional linkages between atherosclerosis and osteoporosis but the 
inflammatory connection is of the most importance to this research.  Given that both 
diseases are inflammatory driven, it may be possible to utilize a therapy that works to 
inhibit both vascular calcification and bone loss.  Also, since the pathogenesis of 
biomaterial wear debris osteolysis follows a similar pattern, preventing the inflammatory 
response may prevent patients from developing other chronic diseases. 
 
Bisphosphonate therapy 
 Bisphosphonates are the current treatment of choice for a variety of bone diseases 
driven by osteoclastic activity.  These diseases include: Paget’s disease, metastatic and 
osteolytic bone disease, hypercalcemia of malignancy and osteoporosis.  
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Bisphosphonates (BPs) have a selectively high affinity for localization and retention in 
bone with low intestinal absorption around 1-4% (Russell, 2006).  Due to their 
preferential uptake by and adsorption to mineral surfaces, the drugs are in very close 
proximity to osteoclasts.  BPs are internalized by osteoclasts, where they affect osteoclast 
recruitment, differentiation and resorptive activity, possibly by causing apoptosis.   
 Bisphosphonates have a P-C-P backbone, with the geminal carbon having the potency 
to bind two radicals: R1 and R2.  When R1 is a hydroxyl group, the binding of the 
compound to hydroxyapatite is increase; whereas the R2 radical supports the efficacy on 
the osteoclast.  The BPs can be divided into two classes: 1) those that contain nitrogen in 
one of their side chains; and 2) those that do not contain nitrogen in the side chain.  The 
BPs that do not contain nitrogen in their R2 side chain (clodronate, etidronate and 
tiludronate) get incorporated into intracellular analogues of adenosine triphosphate (ATP) 
and it is likely that the intracellular accumulation of these metabolites within osteoclasts 
inhibits their function and may cause osteoclast cell death (Russell, 2006).  The nitrogen-
containing BPs (risedronate, zoledronate, alendronate, pamidronate and ibandronate) 
work in the mevalonate pathway where they inhibit prenylation and function of GTP-
binding proteins (Ras, Rab, Rho and Rac) required for osteoclast formation, function and 
survival (Russell, 2006). 
 It is also important to mention the correlation between bisphosphonates and statins.  
Statins are blockbuster drugs used to lower cholesterol through their ability to reduce 
cholesterol biosynthesis by inhibiting HMG-CoA reductase, one of the first steps in the 
mevalonate pathway.  Interestingly, statins have also been shown to inhibit osteoclast 
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formation and bone resorption in in vitro studies (Fisher et al., 1999; Hall, 1998).  
However, when used clinically, there is no substantial evidence that statins are effective 
in preventing bone loss.  This is most likely explained by the fact that statins are 
selectively taken up by the liver and not by bone, which is the opposite effect of 
bisphosphonates. 
 It is thought that BPs are selectively internalized primarily by osteoclasts rather than 
other cell types due to their accumulation in bone.  During the resorption process, the 
space beneath the osteoclast is acidified by the action of vacuolar type proton pumps in 
the ruffled border of the osteoclast membrane (Suda et al., 1997).  The acidic 
environment causes dissolution of the hydroxyapatite bone mineral while the breakdown 
of the extracellular matrix is degraded by proteolytic enzymes.  Since BPs absorb to bone 
mineral, especially at sites of bone resorption where the mineral is exposed, osteoclasts 
are the cell type that are most exposed to free, non-mineral bound BP, as a result of the 
release of the BP from bone mineral in the low pH environment beneath osteoclasts 
(Russell, 2006). 
 While the primary effect of BPs is on osteoclasts, there is also data indicating that 
some of the nitrogen-containing BPs causes apoptosis of macrophages and human 
myeloma cell lines and have effects on Δδ T cells (Rogers et al., 1996; Coxon et al., 
1998; Shipman et al., 1997; Shipman et al., 1998; Moreau et al., 2007).  It is thought that 
while BPs selectively attach to bone mineral, there is probably sufficient amounts of BPs 
entering these cells to inhibit the mevalonate pathway.   
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 As discussed above, the commonality in many diseases is the elevated levels of pro-
inflammatory cytokines and the macrophage is one of the key cells involved in the 
pathogenesis of atherosclerosis and osteolysis.  Thus, any therapy that can inhibit the 
inflammatory response through inactivation of macrophages may also inhibit foam cell 
formation and accumulation of atherogenic cholesterol in arteries (Bevilacqua et al., 
2005) and prevent periprosthetic bone loss.  One such class of drugs that may have dual 
benefit is the bisphosphonates.  Bisphosphonates have also been shown to inhibit wear 
debris mediated bone resorption in animal models of osteolysis (Shanbhag et al., 1997; 
von Knoch et al., 2005; Thadani et al., 2002; Millett et al., 2002; Iwase et al., 2002) as 
well as in humans (Antoniou et al., 2000).  Since osteoclasts and macrophages 
differentiate from the monocyte lineage, it is possible that bisphosphonates not only 
affect bone metabolism but also inflammatory responses (Pietschmann et al., 1998). 
 While their effect on osteoclasts has been studied extensively, much less is known 
about the effects of bisphosphonates on macrophages.  Macrophages are sensitive to 
bisphosphonates and are suppressed at concentrations much lower than would cause 
cytotoxicity (Stevenson and Stevenson, 1986; Mönkkönen et al,, 1994).  More recently, 
Moreau and colleagues (2007) have shown that at low doses the bisphosphonates, 
risedronate and zoledronate induce apoptosis of macrophages in the mouse macrophage-
like J774.1 cell line.  This is an important observation since bisphosphonates, when given 
orally, have poor intestinal absorption (< 1%).  Additionally, bisphosphonates have also 
been shown to inhibit TNF-α release from macrophages exposed to UHMWPE (Huk et 
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al., 2003; Petit et al., 2006) but no effect was seen in macrophages exposed to alumina 
ceramic (Petit et al., 2006), suggesting that the type of particle may play a role.   
 Interestingly, bisphosphonates have also been studied for the prevention or treatment 
of atherosclerosis.  While bisphosphonates predominantly attach to bone, they also 
accumulate in human arterial walls (Lantto et al., 1989; Mori et al., 1992; Ikehira et al., 
1999) and in healthy and atherosclerotic rat aortas (Ylitalo et al., 1996).  From as early as 
the mid-1970’s, bisphosphonates at higher doses were shown to inhibit animal 
experimental atherosclerosis without affecting serum cholesterol or lipid profiles 
(Rosenblum et al., 1975; Kramsch and Chan, 1978; Kramsch et al., 1981; Ylitalo et al., 
1994; Zhu et al., 1994).  More recently, a bisphosphonate at clinical doses has been 
shown to inhibit the intima-media thickening of the carotid artery in humans with type 2 
diabetes being treated for osteopenia (Koshiyama et al., 2000).  The mechanism by which 
bisphosphonates interfere with atherosclerosis may be multi-factorial but one of the key 
events may be macrophage apoptosis by inhibiting intracellular enzymes in the 
cholesterol biosynthesis pathway.  Arterial macrophages play a key role in atherogenesis 
as they ingest modified oxidized low density lipoprotein (LDL) and are then transformed 
to atherogenic foam cells; thus, a therapy that inactivates macrophages may inhibit foam 
cell formation and accumulation of atherogenic cholesterol in the arteries (Bevilacqua et 
al., 2005; Raines and Ross, 1997).  
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 Hypothesis and Research Questions 
 Wear debris from total joint replacements has been shown to elicit an adverse local 
tissue response leading to macrophage activation, cytokine release, local activation of 
adhesion molecules and bone resorption.  Disseminated wear debris from total joint 
replacements, as well as from other biomaterial devices, has also been found in end 
organs and lymph nodes, yet very little is known about its systemic effect on the 
inflammatory system.  The same pro-inflammatory cytokines found in the local tissues 
around failed total joint replacements are also implicated in age-related diseases 
including atherosclerosis, peripheral vascular disease, coronary artery disease, 
osteoporosis, Type 2 Diabetes, dementia and Alzheimer’s disease and some forms of 
arthritis and cancer (Omoigui et al., 2007).   
 It is hypothesized that biomaterial wear debris, which may generated by any type of 
artificial material that is placed in the body, creates a chronic pro-inflammatory state that 
may predispose patients to age related diseases that are mediated by inflammation.  
Furthermore, it is hypothesized that the bisphosphonate, risedronate (Actonel®, Procter & 
Gamble Pharmaceuticals, Cincinnati, OH), will inhibit the expected inflammatory 
response in an in vitro and in vivo model. 
 The objectives of this research were to evaluate the in vitro cellular response to 
different types of wear debris, both as individual cultures of macrophages and endothelial 
cells and as a co-culture; and to evaluate the in vivo response to injections of metallic 
particles into the blood stream of the rat.  A research methodology was developed to 
address the above research hypothesis and answer the following research questions: 
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1. What effect does biomaterial wear debris cultured in a co-culture of macrophages 
and endothelial cells have on the expression of intracellular adhesion molecule -1 
(ICAM-1)? 
 
2. Does the co-culture have to be in contact with the biomaterial debris, or can 
medium from macrophages exposed to particles be added to endothelial cells to 
elicit an increase in ICAM-1?  And, can the bisphosphonate, risedronate, inhibit 
the expected inflammatory response? 
 
3. If stainless steel and commercially pure titanium particles are injected into the tail 
vein of the rat, are the particles disseminated throughout the circulatory system 
after four injections? 
 
4. Does the injection of stainless steel and commercially pure titanium particles into 
the blood stream of the rat elicit an inflammatory response over time? 
 
5. Does the injection of stainless steel particles into the blood stream of the rat elicit 
an increase in IL-6, TNF-α, ICAM-1 and C Reactive Protein (CRP) response as a 
function of time? 
 
6. Can treatment with risedronate prevent the expected the pro-inflammatory 
cytokine and ICAM-1 and CRP response after particle injection? 
 
 
Clinical significance 
 Both osteoporosis and atherosclerosis account for significant morbidity and mortality 
and are independent predictors of cardiovascular disease (Stafford et al., 2004; Kado et 
al., 2000; Jorgensen et al., 2001).  The same pro-inflammatory cytokines implicated in 
age-related diseases including atherosclerosis, peripheral vascular disease, coronary 
artery disease, osteoporosis, Type 2 Diabetes, dementia and Alzheimer’s disease and 
some forms of arthritis and cancer (Omoigui et al., 2007) have also been found in the 
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local tissues around failed total joint replacements.  While the exact mechanisms 
involved have yet to been identified, it has been determined that cytokines, released by 
macrophages that have ingested the wear debris, activate osteoclasts.  While a 
tremendous amount of research has focused on the local response to orthopaedic wear 
debris, there have only been a few studies that have looked at the effect of wear debris on 
the rest of the body. 
 Not only are wear debris generated locally, but studies have found that wear debris is 
also distributed systemically, specifically in the lymph nodes, liver and spleen.  It is 
likely that this debris travels through blood vessels and the lymphatic system.  To date, 
no known studies have evaluated the effect of wear debris on the vascular system.  Thus, 
it is important to characterize the systemic effect of biomaterial wear debris on the 
inflammatory system and to determine if therapeutic interventions can mediate the 
expected inflammatory response.  By preventing further chronic inflammation, it is 
possible to perhaps prevent the development of other chronic diseases, given their 
common pathway and their interactions. 
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RESPONSE OF RAT MACROPHAGES AND ENDOTHELIAL CELLS 
IN CO-CULTURE TO BIOMATERIAL WEAR DEBRIS 
 
 
Abstract 
 
 Biomaterial wear debris has been implicated in the failure of total joint replacements 
due to osteolysis, resulting in revision surgery.  As particulate wear debris is generated, 
macrophages (MAC) ingest the debris which leads to the release of various cytokines that 
activate osteoclasts.  Most research has identified the three cytokines, interleukin-1β (IL-
1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), as important contributors 
to the osteolytic process.  These same cytokines have also been shown to activate 
adhesion molecules on endothelial cells (EC), allowing leukocytes to transmigrate 
through the endothelium.  Monocyte infiltration is an early event in the natural history of 
atherosclerosis and a prominent feature of vasculitis.  Thus, it is possible that the 
activation of adhesion molecules, due to cytokine release induced by wear debris, may 
play a role in vascular disease. 
 The purpose of this study was to evaluate the in vitro vascular response of different 
configurations (non-contact and contact) of co-cultures of MAC and EC treated with 
various materials.  Both metallic (commercially pure titanium) and polymeric (high 
density polyethylene) particles were tested.  In addition, lipopolysaccharide (LPS) was 
used as a positive control. The bisphosphonate, risedronate (Actonel®, Procter & Gamble 
Pharmaceuticals, Cincinnati, OH), was investigated as a possible inhibitor of the induced 
inflammatory response.  Cells with no treatment served as the control group.  
 In the non-contact configuration, neither titanium or polyethylene particles elicited a
significant intracellular adhesion molecule response (ICAM) versus control, although 
they were trends toward treatment effect.  The same effect was also found for the contact 
configuration.  In both configurations, the rank order was the same.  Lipopolysaccharide 
treatment resulted in the highest ICAM response, followed by polyethylene particles, 
cells alone (control), titanium particles, and cells treated with risedronate.  Finally, the 
addition of risedronate resulted in lower, although not statistically different, ICAM values 
than seen in the non-contact and contact configurations, suggesting a potential benefit in 
inhibiting the inflammatory response. 
 To the author’s knowledge, this is the first time a co-culture of macrophage and 
endothelial cells have been treated with biomaterial wear debris to measure the ICAM 
response.  Results from this study suggest that biomaterial wear debris may lead to 
increased levels of ICAM and could potentially influence vascular disease.  Also, the 
bisphosphonate, risedronate, appeared to inhibit the ICAM response seen after exposure 
of the cells to different stimuli.  
 
Introduction 
 Over the past 30-40 years, biomaterials have been used in numerous areas such as 
orthopaedics, vascular surgery, cardiac surgery, facial reconstruction, and dental surgery.  
One of the most common uses of biomaterials is in total joint replacements where 
approximately one million replacements are performed each year with the majority being 
total hip replacements (Ingham and Fisher, 2005).  However, long-term studies of total 
hip replacement have shown a finite failure rate that increases with time, with the most 
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frequent type of failure being aseptic loosening due to osteolysis (Harris, 1995; 
Archibeck et al., 2000).   
 As wear particles are generated, they enter the periprosthetic tissues and are 
phagocytized by macrophages.  Prior research has shown that the activation of 
macrophages in the periprosthetic tissues around joint replacements is stimulated by both 
ultra high molecular weight polyethylene (UHMWPE) and metallic particles.  The 
activation of macrophages is the key factor in the development of osteolysis (Ingham and 
Fisher, 2005; Buly et al., 1992; Nasser et al., 1989; Nasser et al., 1990).  After the 
ingestion of particles, the macrophages then release a variety of cytokines and other 
mediators of inflammation that eventually leads to the activation of osteoclasts and 
loosening of the prosthesis.   
 Some of the cytokines that have been identified in periprosthetic tissues include: IL-
1β, IL-6, TNF-α, IL-8, IL-11, and TGF-β (Xu et al., 1996; Kim et al., 1993; Sabokbar 
and Rushton, 1995; Al-Saffar et al., 1995).  Other factors identified include matrix 
metalloproteinases (MMP-1, MMP-2, and MMP-11), tissue inhibitors of 
metalloproteinases and elastase (Archibeck et al., 2000; Al-Saffar, 1999).  In addition to 
the above in vivo findings, many cell culture experiments have shown that human and 
animal macrophages release IL-1, IL-6, TNF-α and PGE2 in the presence of different 
wear particles, including: polymethylmethacrylate (PMMA), UHMWPE, high density 
polyethylene (HDPE), commercially pure titanium (cpTi), Ti6AL4V (retrieved and 
fabricated), CoCr (retrieved and fabricated) and stainless steel (Murray and Rushton, 
1990; Westacott et al., 1992; Shanbhag et al., 1995; Algan et al., 1996; Sun et al., 1996; 
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Lee et al., 1997; Haynes et al., 1998; Nakashima et al., 1999; Robinson et al., 1999, Xing 
et al., 1999; Davis et al., 1993; Glant and Jacobs, 1994; Gonzalez et al., 1996; Horowitz 
et al., 1993; Shanbhag et al., 1994). 
 The data suggest that all of the above cytokines and mediators are derived from 
particle-activated macrophages and contribute to the inflammatory response by activating 
endothelial cells (Al-Saffar et al., 1994; Al-Saffar et al., 1995).  Endothelial cell 
activation and the expression of adhesion molecules related to wear debris have been 
demonstrated in three in vivo studies.  Sabokbar and Rushton (1995) found significantly 
elevated levels of PGE2, IL-6, IL-8 and adhesion molecules (soluble intercellular 
adhesion molecule, soluble vascular adhesion molecule, and soluble endothelial 
leukocyte adhesion molecule) in the fluid taken from patients with loose hip prostheses.  
Al-Saffar and coworkers (1995) described a histological pattern of vascular growth and 
demonstrated the induction and upregulation of three types of adhesion molecules in the 
bone-implant interface of aseptically loosened protheses: endothelial leukocyte adhesion 
molecule-1 (E-selectin); intercellular adhesion molecule-1 (ICAM-1); and vascular cell 
adhesion molecule-1 (VCAM-1).  Finally, a study aimed at characterizing the response of 
capillaries and postcapillary venules of striated muscle to submicron particles of stainless 
steel or commercially pure titanium showed that the wear particles led to the activation of 
leukocytes with a notable increase in the leukocyte endothelial-cell interaction (Kraft et 
al., 2001). 
 The effect of wear debris on the vascular system could potentially have major 
implications.  For example, vascular calcifications have been proposed as a response 
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mechanism to injury resulting from chronic metabolic toxicities (Bevilacqua et al., 2005).  
Chronic toxicity would cause stimulation of nuclear factor kappaB which would then 
activate TNF-α, IL-1, IL-6 and other inflammatory markers such as C-reactive protein 
(Hayden et al., 2005).  Increased levels of ICAM-1 are also associated with a variety of 
inflammatory conditions, one of which is atherosclerosis (Watanabe and Fan, 1998).  In 
atherosclerosis, adhesion molecule activation leads to the transmigration of cells in the 
bloodstream through the endothelium into the tunica media.  At this point, macrophages 
ingest oxidized lipids and become foam cells leading to an atherosclerotic plaque.  It has 
been shown that ingestion of wear debris by macrophages leads to the release of 
inflammatory cytokines and local activation of adhesion molecules.  One area that has not 
been explored is the effect of prosthetic wear debris on vascular disease.  As previously 
described, cytokine release as a result of biomaterial wear debris have been shown to lead 
to the activation of adhesion molecules on endothelial cells at a local level, but a systemic 
response has not been addressed.  Since wear debris has been shown to travel throughout 
the body, it is important to understand what effect systemic wear debris would have on 
the vascular system. 
 If biomaterial wear debris increases systemic inflammation, it would be advantageous 
to have a therapy that would inhibit the inflammatory response without affecting other 
physiological systems.  Bisphosphonates are stable analogues of a naturally occurring 
pyrophosphate compound that inhibit bone resorption by the preferential uptake by and 
adsorption to mineral surfaces in bone that bring them into close contact with osteoclasts 
(Russell, 2006).  They can affect osteoclast-mediated bone resorption in a variety of ways 
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that include effects on osteoclast recruitment, differentiation, and resorptive activity, and 
may induce apoptosis (Russell, 2006).  Bisphosphonates are the treatment of choice for a 
variety of bone diseases in which excessive osteoclast activity is an important 
pathological feature, including Paget’s disease of bone, metastatic and osteolytic bone 
disease, and hypercalcemia of malignancy, as well as osteoporosis (Russell, 2006).  In 
addition, bisphosphonates inactivate not only osteoclasts but also suppress macrophages, 
the cells having a key role in atherogenesis (Ylitalo, 2002).  Macrophages and some other 
endocytotic cells are able to internalize bisphosphonates, after which the drugs may 
interact with enzymes or other targets in the cell and affect cellular metabolism and lead 
to apoptosis of the macrophage (Fast et al., 1978; Felix et al., 1984; Sato et al., 1991; 
Rogers et al., 1997; Rogers et al., 2000).  Bisphosphonates have been shown to inhibit the 
development of experimental atherosclerosis without affecting serum cholesterol or lipid 
profile (Rosenblum et al., 1975; Kramsch and Chan, 1978; Kramsch et al., 1981; Ylitalo 
et al., 1994; Zhu et al., 1994).  In 2000, Koshiyma and colleagues demonstrated that the 
bisphosphonate, etidronate, inhibited the intima-media thickening of the carotid artery in 
humans.  Additionally, in animal models of restenosis, the partial systemic inactivation 
and transient depletion of monocytes and macrophages by liposomal bisphosphonates has 
been shown to reduce neointimal hyperplasia and restenosis (Danenberg et al., 2002; 
Danenberg et al., 2003; Danenberg et al., 2003).  While the exact manner mechanism has 
not been elucidated, it appears that the drugs have a direct effect on the arterial wall, 
where they may interact with the subendothelial lipid-phagocytizing cells (Ylitalo, 2002).  
Bisphosphonates have also been shown to accumulate in the arterial walls and suppress 
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the accumulation of atherogenic lipoproteins in macrophages, which may play a key role 
in atherogenesis (Bevilacqua et al., 2005). 
 The purpose of this in vitro study was to analyze the effect of different biomaterial 
particles on the adhesion molecule response when exposed to macrophage and 
endothelial cells via a direct contact co-culture and an indirect culture of media from 
activated macrophages and endothelial cells.  An additional objective was to determine 
what effect, if any, the bisphosphonate, risedronate, had on inhibiting adhesion molecule 
response in the presence of different biomaterials.  It was hypothesized that biomaterial 
particles would lead to a pro-inflammatory response and activation of intracellular 
adhesion molecule-1 (ICAM-1) and that the inflammatory response would be inhibited 
by the addition of risedronate to the culture system. 
 
Materials and Methods 
 
Material Selection 
 The materials chosen for this study were commercially pure titanium particles (cpTi, 
Aldrich Chemical Company, Inc., Milwaukee, WI) and high density polyethylene powder 
(HDPE, USI Chemicals).  These materials were chosen due to their extensive use as 
biomaterials, including orthopaedic and vascular applications, catheters, plastic and 
reconstruction surgery and many other uses.  The particles were chosen based on the 
sizes of wear debris retrieved from periprosthetic tissues of failed implants.  Several 
studies have shown that the mean size of retrieved polyethylene and metallic particles is 
around 0.5-0.6 μm but can range from 0.1 μm up to several hundred microns (Willert and 
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Buchhorn, 1993; Shanbhag et al., 2000; Maloney et al., 1995; Margevicius et al., 1994).   
The manufacturer reported size range for cpTi was 1-3 microns and less than 20 microns 
for HDPE.   
 
Material Characterization 
 In order to determine the size and amount of particles for each type of material, the 
particles were analyzed by an AccuSizer™ 770 Optical Particle Sizer (NICOMP Particle 
Sizing Systems, Inc., Santa Barbara, CA).  Particles of each material were analyzed to 
determine mean diameter, number of particles in the amount tested and the distribution of 
sizes. 
 
Material Preparation 
 Both high density polyethylene and titanium particles were measured out to obtain 
doses of 1 x 108 particles per well and then the particles were sterilized.  Of note, it was 
decided not to remove endotoxin from the particles for several reasons.  First, recent 
studies that have focused on adherent endotoxin were specifically analyzing the effect of 
orthopaedic wear particles on osteolysis whereas this study was focused on the effect of 
biomaterials on the activation of intracellular adhesion molecule (ICAM), where very 
little data is available and thus the effect is unknown (Greenfield et al., 2004; Tatro et al., 
2006; Baumann et al., 2005).  Additionally, it has been shown by Ragab and coworkers 
(1999) that implants, as received from suppliers, contain substantial amounts of adherent 
endotoxin.  Another reason is that Greenfield and associates (2004) reported that the high 
affinity of wear particles for endotoxin may lead to accumulation of circulating endotoxin 
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derived from intestinal flora, minor infections, or dental procedures on the wear particles 
after they are generated in patients.  Finally, while cytokine production is significantly 
lower after exposure to endotoxin free particles than particles containing endotoxin, there 
is still release of TNF-α which may then lead to activation of ICAM. 
 
Bisphosphonate Selection 
 Risedronate (Actonel®, Procter & Gamble Pharmaceuticals, Cincinnati, OH), a 
nitrogen-containing bisphosphonate, was evaluated in this study as a potential inhibitor of 
adhesion molecule activation.  Risedronate is FDA approved for the treatment and 
prevention of postmenopausal osteoporosis. 
 
Macrophage Cell Culture 
 Rat macrophage cells (CRL-2192, designation NR8383, Sprague Dawley Isotype Rat, 
ATCC, Manassas, VA) were shipped cryopreserved at the end of their tertiary culture in 
the appropriate culture medium and 5% dimethylsulfoxide (DMSO) (Sigma, St. Louis, 
MO).  Based on ATCC's product information sheet, the macrophage cells were 
phagocytotic and were capable of the release of the following cytokines Interleukin-1, 
Interleukin-6, and Tumor Necrosis Factor-alpha, (IL-1, IL-6 and TNF-α) respectively.  
Cells were sub-cultivated in T-150 culture flasks (Corning canted neck flasks with vented 
caps, VWR, Atlanta, GA) in a 37°C, 5% CO2, 95% air, humidified culture incubator with 
25 mL of Hams F-12 (N-6658, Sigma, St. Louis, MO) with sodium bicarbonate and L-
glutamine plus 10% heat inactivated fetal bovine serum (FBS, F-4135, Sigma, St. Louis, 
MO) plus 1% antibiotic/antimycotic solution (A-5955, Sigma, St. Louis, MO).  After the 
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cells were sub-cultivated, they were aliquoted into vials, at 20 million cells per vial, and 
maintained in Liquid Nitrogen (-176oC) for later use.  All cells used were between 
passage 2 and 5. 
   
Endothelial Cell Culture 
 Rat aortic endothelial cells (RAEC, Sprague Dawley Isotype Rat, VEC Technologies, 
Inc., Rensselaer, NY) were shipped cryopreserved in the appropriate culture medium and 
5% dimethylsulfoxide (DMSO) (Sigma, St. Louis, MO).  Prior to subcultivation, pyrogen 
free Type B Gelatin from bovine skin (G-1393, Sigma, St. Louis, MO) was diluted in 
Dulbecco's phosphate buffered saline (DPBS, D-8537, Sigma, St. Louis, MO) to a 0.2% 
solution and was coated on all RAEC flasks and plates.  The solution was then aspirated, 
and the flasks and plates were allowed to dry under a class 2 A/B3 biological safety 
cabinet while exposed to ultraviolet light (UV) overnight.  Proliferating RAEC were 
maintained in MCDB-131 Complete (10% FBS, 1% Antibiotic) Medium (VEC 
Technologies, Inc., Rensselaer, NY), using the prepared plates as described above.  After 
the cells were sub-cultivated, they were aliquoted into vials, at 20 million cells per vial, 
and maintained in Liquid Nitrogen (-176°C) for later use.  All cells used were between 
passages 2 and 5. 
 
Medium Determination 
 In order to test for in vitro activation of adhesion molecules on the surface of 
endothelial cells, a co-culture of macrophages and endothelial cells was needed.  Since 
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the two cell types had to be grown together, a medium that would sustain both endothelial 
cells and macrophages was required. 
 Two types of medium were tested: (1) Hams F-12 with sodium bicarbonate and L-
glutamine plus 10% fetal bovine serum (FBS) plus 1% antibiotic/antimycotic solution 
and (2) MCDB-131 plus 10% fetal bovine serum (FBS) plus 1% antibiotic/antimycotic 
solution.  Each cell type was grown individually to determine which medium worked best 
for each specific cell type.  In addition, co-cultures were grown in each medium to 
determine which medium would be best for the co-culture system.  Also, a gelatin 
coating, described above, was utilized to help with endothelial cell proliferation and was 
applied to the polystyrene culture plate.  Live/dead assays were conducted to determine 
which medium supported the most cell growth. 
 
Live/Dead Assay 
 A live/dead assay kit (LIVE/DEAD® Viability/Cytotoxicity Assay Kit, L-3224, 
Molecular Probes, Eugene, OR) was used to determine cell number and viability.  Cells 
were released from the wells by using a 0.25% trypsin digest (Trypsin/EDTA, Trypsin 
Neutralizer, Cascade Biologics, Inc.) and counted in a hemocytometer.  Live and dead 
cells were counted in each well, for a total of four wells per group.  The percentage of 
viable cells for each condition was found by multiplying the ratio of live cells to total 
cells (live plus dead cells) by 100.  Mean percentages and a standard deviation were also 
calculated.  Based on the results from the medium test, it was determined that the 
MCDB-131 medium worked best for both macrophage and endothelial cell growth and 
proliferation.  Thus, this medium was used for the remaining cell culture studies.  In 
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addition, it was determined that the gelatin coating, as described previously for EC 
culture, allowed for the growth and proliferation of endothelial cells and was used for all 
individual EC studies as well as in the co-culture. 
 
Cell Co-Culture Setup 
 In order to determine the effect of different biomaterials on adhesion molecule 
activation, a co-culture system was designed.  This system tested the interaction of 
biomaterial wear particles with macrophage and endothelial cells via a non-contact and a 
contact configuration and also evaluated the effect of risedronate, in a contact 
configuration, on the adhesion molecule response.  Endothelial cells only were also 
exposed to the different treatments. 
 
 Non-contact Setup 
 Individual cultures of macrophages and endothelial cells were seeded at 1 x 106 
cells/well in two 24 well plates with 1 mL of the MCDB-131 medium and allowed to 
incubate for 24 hours.  Of note, due to the fact that polyethylene particles float, 
macrophages used for polyethylene tests were grown on 0.4 μm pore polycarbonate 
inserts (VWR, Atlanta, GA) such that the cells would be in contact with the 
polyethylene.  After 24 hours, the macrophage plate was removed from the incubator 
and prepared for particle addition.  The following treatments were added to the 
macrophage plate and tested at a sample size of three: commercially pure titanium 
particles (1 x 108 particles/well); high density polyethylene particles (1 x 108 
particles/well); lipopolysaccharide (LPS) as a positive control at 4 endotoxin units 
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(EU)/100 μL/well (Sigma, St. Louis, MO); risedronate (1.67 mg/well); and no 
treatment.  After the treatments were added to the wells, the plate was then returned 
to the incubator for an additional 24 hours.  Following the 24 hour incubation period, 
the plate was removed and the medium was harvested and added to the plate of ECs 
and then incubated for an additional 24 hours.  After the last incubation period, the 
medium was collected and centrifuged to remove particulates and stored at -20°C for 
further analysis. 
 
 Contact Setup 
 For the contact configuration, macrophages were seeded at 1 x 106 cells/well on 
0.4 μm pore polycarbonate inserts (VWR, Atlanta, GA) and endothelial cells were 
seeded at 1 x 106 cells/well in two 24 well plates and incubated for 24 hours.   After 
24 hours, the macrophage inserts were exposed to the different treatments and 
concentrations as described above and placed in the wells of the endothelial plate.  
Following the 24 hour incubation period, the medium was collected and centrifuged 
to remove particulates and stored at -20°C for further analysis. 
 
 Contact plus Risedronate and Endothelial Cells Alone Setups 
 The contact plus risedronate setup was designed the same as described in the 
previous section except that 1.67 mg of risedronate was added to each well of 
treatments.  The endothelial cell setup was composed of endothelial cells only that 
were treated with the cpTi, HDPE, LPS, cells only and cells plus RIS. 
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sICAM-1 assay 
 Levels of rat soluble intercellular adhesion molecule-1 (sICAM-1) concentrations 
were measured from the harvested cell culture supernate using a commercially available 
ELISA kit (Quantikine®, R&D Systems, Minneapolis, MN).  At the time of testing, the 
cell culture supernate was thawed at room temperature and then concentrated using a 
Centriprep® Centrifugal Filter Unit (Millipore, Jaffrey, NH).  Once ready for analysis, 
the cell culture supernate was tested for expression of the adhesion molecule sICAM-1 as 
directed in the kit instructions. 
 
Statistical Analysis 
 Analysis of variance (ANOVA) was used to test for differences in mean sICAM-1 
values using SigmaStat Version 3.5 (Systat Software Inc., Richmond, CA).  If the overall 
p-value from the F-test was significant, then multiple comparisons were made using 
Student-Newman-Keuls Method.  P-values < 0.05 were considered indicative of 
statistical significance.   
 
Results 
Material Characterization 
 A particle size analyzer was used to determine the size, size range and number of 
particles in a known mass of material (Model 770 AccuSizer, Particle Sizing Systems, 
Inc., Santa Barbara, CA).  The mean diameter and standard deviation of the cpTi particles 
was 2.09 μm ± 2.16 μm and 35% of the particles were less than 1 μm.  Also, 99% of 
these particles were less than 10.55 μm.  In an 8.8 mg sample of cpTi, the analyzer 
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determined that there were 1.24 x 108 particles.  Finally, the mean diameter and standard 
deviation of the HDPE particles was 11.26 μm ± 8.07 μm with 5% of the particles being 
in the submicron range.  The HDPE particles had a more varied size range, with 99% of 
the particles being less than 38.52 μm.  For a 5.5 mg sample of HDPE, the number of 
particles was found to be 6.24 x 106.  Results from the particle size analysis can be found 
in Table 1.1 and a complete analysis of the test materials can be found in Appendix A. 
 
 
Table 1.1  Material size and distribution analysis. 
Measurement HDPE cpTi 
Mean Diameter (μm) 11.26 2.09 
Standard Deviation (μm) 8.07 2.16 
50% of total particle number (μm) < 9.47 < 1.26 
99% of total particle number (μm) < 38.52 < 10.55 
Number of particles in sample 6.24 x 106 1.24 x 108
 
 
Live/Dead Assay 
 The live/dead assay was performed to determine which medium allowed the greatest 
cell viability, particularly in endothelial cells.  Initially, there was much difficulty in 
achieving appropriate endothelial cell viability and confluency.  Based on 
recommendations from the supplier, a 0.2% gelatin coating was used to coat the plates 
and flasks that were used to grow the endothelial cells.  Live/dead assays were conducted 
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to see if the gelatin coating improved endothelial cell proliferation and to see which 
medium the endothelial cells grew in the best.  These results are shown in Table 1.2. 
 
 
Table 1.2  Results of live/dead assay for endothelial cells. 
Treatment Mean percent 
viability (n = 4) 
Standard deviation 
MCDB-131 
with gelatin 
 
93% 
 
1% 
MCDB-131 
without gelatin 
 
90% 
 
3% 
Hams F12 
with gelatin 
 
26% 
 
10% 
Hams F12 
without gelatin 
 
7% 
 
3% 
 
 
 
 The greatest endothelial cell viability was achieved when the cells were grown in the 
MCDB-131 medium and in gelatin coated plates.  Thus, this technique was used 
throughout the study for both cultivation and proliferation of endothelial cells.  The next 
step was to determine if the macrophages would grow appropriately in the MCDB-131 
medium.  A live/dead assay was used to determine the percent viability of macrophages 
in both Hams F12 and MCDB-131 media.  The percent viability for the macrophages in 
the Hams F12 was 89% ± 1% and 90% ± 2% with the MCDB-131 medium.  There was 
no difference in macrophage viability between the two media and therefore the MCDB-
131 medium was chosen for all of the co-culture tests. 
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sICAM-1 Results 
 Utilizing the non-contact and contact configurations described previously, co-cultures 
of macrophages and endothelial cells were grown and treated with commercially pure 
titanium (cpTi) particles, high density polyethylene (HDPE) particles, lipopolysaccharide 
(LPS), and risedronate (RIS).  Co-cultures with no treatment served as a control.  First, 
the data are presented separately for comparison within each configuration (non-contact, 
contact, contact plus risedronate and endothelial cells alone) to determine the effect of 
treatment.  Secondly, the treatments will be compared across configurations to determine 
the effect of non-contact versus contact. 
  
 Non-contact Configuration 
 sICAM-1 concentrations were measured after 24 hours of exposure and are shown 
in Figure 1.1.  Non-treated cells were used as the control.  ANOVA analysis indicated 
a significant difference within the non-contact configuration (p=0.024).  However, 
there was no significant difference between any of the treatment sICAM-1 values 
versus control.  In addition to comparisons between treatments and the control, 
comparisons were also made across treatments within the non-contact group.  
Cultures treated with LPS exhibited a significantly higher sICAM-1 response than 
titanium or risedronate (p=0.046 and p=0.021, respectively).  There were no other 
significant differences across the treatment groups.  Within the group, the numerical 
rank order was: LPS, HDPE, control (cells only), titanium and risedronate.  The mean 
sICAM-1 values for each treatment are presented in Table 1.3 along with the standard 
error of mean (SEM). 
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Table 1.3  sICAM-1 response for each treatment within the non-contact 
configuration.  Data are presented as mean ± standard error of mean (SEM).   
 
 
Treatment Mean ± SEM 
(pg/mL) 
Lipopolysaccharide 
(n=9) 
 
1935 ± 332 
High density polyethylene 
(n=9) 
 
1429 ± 353 
Control (cells only) 
(n=9) 
 
1225 ± 300 
Commercially pure titanium 
(n=9) 
 
885 ± 169 
Risedronate 
(n=9) 
 
696 ± 144 
 
 
 Contact Configuration 
 Initial comparisons were made between the control group and the different 
treatments and are shown in Figure 1.2.  Statistical analysis indicated a significant 
difference within the contact configuration (p=0.012) and thus comparisons between 
treatment groups were performed.  The various treatments were compared to control 
and there was no significant difference found.  The only significant difference found 
within the contact configuration was between LPS and cells treated with risedronate 
(p=0.010).  There was a trend toward significance with the LPS versus titanium 
groups (p=0.061).  As with the non-contact configuration, the rank order within the 
contact configuration was: LPS, HDPE, control (cells only), titanium and risedronate.  
The sICAM-1 values for each treatment within the contact configuration are given in 
Table 1.4. 
 
 61
Table 1.4  sICAM-1 response for each treatment within the contact configuration.  
Data are presented as mean ± standard error of mean (SEM).   
 
 
Treatment Mean ± SEM 
(pg/mL) 
Lipopolysaccharide 
(n=9) 
 
1927 ± 272 
High density polyethylene 
(n=9) 
 
1582 ± 193 
Control (cells only) 
(n=9) 
 
1540 ± 234 
Commercially pure titanium 
(n=9) 
 
1165 ± 158 
Risedronate 
(n=9) 
 
898 ± 158 
 
 
 Contact Configuration Plus Risedronate 
 sICAM-1 concentrations for the different treatments plus risedronate were 
compared to control (cells alone) and are shown in Figure 1.3.  There was no 
difference between the control group and the cpTi, LPS, HDPE or cells only plus 
risedronate treatments.  Lastly, there were no significant differences seen across the 
within group comparisons.  However, whereas the non-contact and contact 
configurations exhibited the same rank order sICAM-1 response, in the contact plus 
risedronate configuration, the rank order changed.  In this configuration, the control 
group (cells only) was found to have the highest sICAM-1 response followed by LPS, 
cells plus risedronate, titanium and HDPE.  The sICAM-1values for each treatment 
within the contact plus risedronate configuration are given in Table 1.5. 
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Table 1.5  sICAM-1 response for each treatment within the contact plus risedronate 
configuration.  Data are presented as mean ± standard error of mean (SEM).   
 
 
Treatment Mean ± SEM 
(pg/mL) 
Control (cells only) 
(n=9) 
 
1436 ± 197 
Lipopolysaccharide 
(n=9) 
 
1230 ± 139 
Risedronate 
(n=9) 
 
1205 ± 118 
Commercially pure titanium 
(n=9) 
 
1108 ± 95 
High density polyethylene 
(n=9) 
 
1106 ± 171 
 
  
 Endothelial Cells Only 
 Figure 1.4 shows the effect of various treatments on endothelial cells alone.  The 
ICAM response was minimal compared to the co-culture setups described previously.  
Endothelial cells treated with LPS had a significantly higher ICAM response than 
ECs alone (p<0.05).  There was no difference between cells treated with HDPE, cpTi 
or risedronate versus cells alone.  Within the group, LPS treatment yielded a 
significantly higher sICAM-1 response than did HDPE, risedronate or cpTi (p<0.05).  
The sICAM-1 values for each treatment within the endothelial cell only configuration 
are given in Table 1.6. 
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Table 1.6  sICAM-1 response for each treatment within the endothelial cell only 
configuration.  Data are presented as mean ± standard error of mean (SEM).   
 
 
Treatment Mean ± SEM 
(pg/mL) 
Lipopolysaccharide 
 (n=9) 
 
66 ± 14 
Commercially pure titanium  
(n=9) 
 
32 ± 4 
Risedronate 
(n=9) 
 
36 ± 9 
High density polyethylene  
(n=9) 
 
27 ± 4 
Control (cells only) 
(n=9) 
 
26 ± 5 
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Figure 1.1  Serum intracellular adhesion molecule-1 (sICAM-1) concentrations for the 
different treatments in a non-contact configuration.  Cells only group was the control.  (*) 
indicates statistical difference from LPS (p<0.05). 
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Figure 1.2  Serum intracellular adhesion molecule-1 (sICAM-1) concentrations for the 
different treatments in a contact configuration.  Cells only group was the control.  (*) 
indicates statistical difference from LPS (p<0.05). 
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Figure 1.3  Serum intracellular adhesion molecule-1 (sICAM-1) concentrations for the 
different treatments in a contact plus risedronate configuration.  Cells only group was the 
control.  There were no significant differences between groups. 
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Figure 1.4  Serum intracellular adhesion molecule-1 (sICAM-1) concentrations for the 
different treatments exposed to endothelial cells only.  Cells only group was the control.  
(*) indicates statistical difference from LPS (p<0.05). 
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Between Group Comparisons 
 
 In order to determine the effect of the different configurations on the sICAM-1 
response, each treatment was analyzed and comparisons were made across the four 
different configurations (non-contact, contact, contact plus risedronate and 
endothelial cells only).  Figure 1.5 depicts the five treatment groups and the four 
different configurations.  Endothelial cell response was significantly lower than the 
other configurations and exhibited a very minimal response.  There were no 
significant differences across configurations for each treatment.  The sICAM-1 values 
for the different configurations and treatments are given in Table 1.7. 
 
 
Table 1.7  sICAM-1 response for each configuration and treatment group.  Data are 
presented as mean ± standard error of mean (SEM).  N=9 per treatment per 
configuration.  Units are pg/mL. 
 
 
Configuration Titanium HDPE LPS Control RIS 
Non-contact 885 ± 169 1429 ± 353 1935 ± 332 1225 ± 300 696 ± 144 
Contact 1165 ± 158 1582 ± 193 1927 ± 272 1540 ± 234 898 ± 158 
Contact + 
Risedronate 
 
1108 ± 95 
 
1106 ± 171 
 
1230 ± 139 
 
1436 ± 197 
 
1205 ± 
118 
Endothelial 
Cells only 
 
32 ± 4 
 
27 ± 4 
 
66 ± 14 
 
26 ± 5 
 
36 ± 9 
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Figure 1.5  Serum intracellular adhesion molecule-1 (sICAM-1) concentrations for the 
different treatments and the four different configurations (Contact+RIS = contact plus 
risedronate; ECs = endothelial cells only).  Cells only group was the control.  (*) 
indicates statistical difference from all groups (p<0.05). 
 
 
 
 
 
 
 
 
 
 68
Discussion 
 Patients with osteoporosis frequently display vascular diseases, including 
atherosclerosis and arterial calcification, a phenomenon that has been observed for over 
one hundred years (Hofbauer et al., 2007).  One of common mechanisms in the 
pathogenesis of osteoporosis and vascular diseases is chronic inflammation (Demer, 
2002).  In fact, several studies have analyzed the effect of bisphosphonates, drugs 
commonly prescribed for osteoporosis, on the prevention of experimental atherosclerosis 
and the reduction of neointimal hyperplasia and restenosis in animal models (Rosenblum 
et al., 1975; Kramsch and Chan, 1978; Kramsch et al., 1981; Ylitalo et al., 1994; Zhu et 
al., 1994; Koshiyma, 2000; Ylitalo, 2002, Danenberg et al., 2002; Danenberg et al., 
2003).  The bisphosphonates act on the mevalonate pathway by inhibiting key enzymes 
necessary for osteoclastic activity.  However, bisphosphonates inactivate not only 
osteoclasts but also suppress macrophages, the cells having a key role in atherogenesis 
(Ylitalo, 2002) as well as in osteolysis (Ingham and Fisher, 2005).   
 The purpose of this study was to evaluate the in vitro response of a co-culture of 
macrophage and endothelial cells to different types of treatments and to determine if 
there was a difference between different contact configuration methods.  In the non-
contact and contact configurations, the ICAM response followed a similar pattern.  LPS 
exhibited the highest response followed by high density polyethylene, cells alone, 
titanium, and risedronate.  In the contact plus risedronate group, the rank order changed 
due to the presence of risedronate with all of the treatments being numerically lower than 
cells alone.  Finally, while no significant difference was found across the different 
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treatments in the non-contact, contact and contact plus risedronate groups, in most cases, 
the numerical ICAM response was greater with the contact configuration versus the non-
contact configuration.  In addition, the contact plus risedronate configuration yielded 
numerically lower ICAM values the contact configuration alone.  These findings will be 
discussed in more detail in the following paragraphs. 
 This study utilized particles similar to that found in the surrounding tissues of failed 
total joint replacements.  The polymeric component of most total joint replacements is 
ultra high molecular weight polyethylene.  However, in this study, high density 
polyethylene was used because the particle size was more similar to that retrieved from 
tissues of failed total joint replacements and because high density polyethylene is used in 
other biomaterials that may generate wear particles.  The mean diameter of the high 
density particles was 11.26 µm and the mean diameter from retrieved particles from 
tissues was submicron from failed total hip replacements and approximately 1.7 µm from 
failed total knee replacements (Campbell et al., 1996; Shanbhag et al., 1994; Maloney et 
al., 1995; Shanbhag et al., 2000).  Additionally, Green and coworkers (1998) 
demonstrated that polyethylene particles ranging from 0.3-10 µm appeared to be the most 
biologically active and in this the study, approximately 55% of the high density 
polyethylene particles were less than 10 µm.  Titanium, either commercially pure or as an 
alloy, is also used widely in the medical field such as in: joint replacement parts for hip, 
knee, shoulder, spine, elbow and wrist; bone fixation materials such as nails, screws, nuts 
and plates; dental implants and parts for orthodontic surgery and dental prosthetics; heart 
pacemaker housings and artificial heart valves; surgical instruments for heart and eye 
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surgery; and components in high-speed blood centrifuges.  Due to its extensive use, 
commercially pure titanium (cpTi) was chosen for this study and the size of the 
commercially pure titanium particles closely approximated those retrieved from failed 
joints.  Several retrieval studies have shown that the mean size of titanium particles from 
tissues surrounding failed prostheses ranged from submicron to 5 µm (Hanlon et al., 
1992; Langkamer et al., 1992; Maloney et al., 1992; Maloney et al., 1995).  The particles 
used in this study had a mean diameter of 2.09 µm. 
 Co-cultures of macrophages and endothelial cells have been studied previously in 
models of atherosclerosis.  However, to the author’s knowledge, this type of co-culture 
has not been used to study the effect of orthopaedic wear debris.  The first step was to 
find a medium that supported the growth of both types of cells.  Utilizing live/dead 
assays, it was determined that a 0.2% gelatin coating and MCDB-131 medium led to the 
greatest endothelial cell viability and MCDB-131 supported macrophage viability as 
well.  The co-culture system was then used to test the in vitro response of macrophage 
and endothelial cells to different types of treatments (commercially pure titanium, high 
density polyethylene, lipopolysaccharide, and risedronate) and to determine if there was a 
difference between different contact configuration methods.  
 In the non-contact configuration, none of the treatments showed significant 
differences over control (cells alone).  LPS, as the positive control, exhibited the highest 
ICAM response followed by HDPE, cells only, cpTi and risedronate.  While the two 
biomaterials tested, titanium and HDPE, did not yield a significant difference, there were 
numerical differences in the ICAM response to the particles.  Titanium treatment was 
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numerically lower than control and HDPE was higher but due to the large standard 
deviations and the number of observations, the overall effect was not significant.  When 
comparing all treatments within the non-contact configuration group, only two 
differences were found.  The ICAM response from LPS was significantly higher than 
both titanium and cells treated with risedronate (p=0.021 and p=0.046, respectively).  
However, this method did demonstrate an ICAM response by exposing the endothelial 
cells to activated medium from macrophages cultured with the different treatments with 
no direct contract between the two cell types. 
 The contact configuration exhibited similar results to the non-contact configuration 
with no differences noted between the various treatments and the control group.  The 
rank order was the same in the non-contact and the contact configurations with LPS 
exhibiting the highest ICAM response, followed by HDPE, cells only, titanium and 
risedronate.  There was a significant difference between LPS and cells treated with 
risedronate but no other differences were found across the group.  Although there were 
numerical differences in the ICAM response, as with the contact configuration, the 
standard deviations were high and a statistical difference versus control was not found.  It 
is possible that by increasing the power of the study, differences would be seen. 
 Previous in vitro studies have shown that macrophages, exposed to different 
biomaterial wear debris, release various pro-inflammatory cytokines (TNF-α, IL-6, PGE2, 
etc.).  However, to the author’s knowledge, no co-culture study has studied the effect of 
debris on intracellular adhesion molecule-1 (ICAM-1).  The above results demonstrate 
that when co-cultures of macrophages and endothelial cells are exposed to different 
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stimuli, cytokines are released that then lead to an effect of ICAM-1.  Endothelial cells 
constitutively express low levels of three immunoglobulin molecules, ICAM-1, ICAM-2, 
and vascular adhesion molecule (VCAM) but treatment with interleukin 1 (IL-1) and 
TNF-α strongly increases ICAM-1 and VCAM synthesis, while ICAM-2 is not affected 
(Springer, 1990;  Rice et al., 1990; Dustin and Springer, 1988; Rice and Bevilacqua, 
1989; Stauton et al., 1989).  In this study, cytokine release was not measured as this was 
not the primary goal of the study.  While there was little statistical difference between the 
non-contact and contact configurations, numerically, the non-contact configuration 
exhibited lower ICAM values than did the contact configuration for all treatments except 
LPS, which was about the same between the two groups.  These data suggest that 
growing the two cell types in the same plate may lead to a higher ICAM response than by 
exposing the endothelial cells to the macrophage media. 
 In addition to the testing configurations, the other goal of this study was to determine 
if the nitrogen containing bisphosphonate, risedronate, had any effect on the measured 
ICAM response from co-culture exposure to the different treatments.  In the contact plus 
risedronate group, co-cultures of macrophages and endothelial cells were exposed to both 
different treatments and to risedronate.  Unlike the non-contact and contact 
configurations, the highest ICAM response seen in the contact plus risedronate group was 
in the control group (cells only).  There were no statistical differences versus control but 
the LPS, titanium and HDPE values were numerically lower, suggesting a potential 
benefit of the addition of risedronate.  In the other configurations both LPS and HDPE 
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consistently exhibited higher values than cells alone and by adding risedronate, the values 
decreased to levels lower than the control.   
 In conclusion, this study demonstrated that a co-culture of macrophages and 
endothelial cells exposed to different treatments in different configurations, exhibited an 
ICAM response not measured before.  Also, the addition of risedronate to the co-culture 
appeared to result in a decrease in ICAM response, perhaps indicative of a reduction in 
inflammatory cytokines.  While there were few significant differences across the 
treatments and configurations, the data may suggest potential differences if the power of 
the study were increased.  In order to determine the systemic effect of biomaterial wear 
debris and its effect on vascular response, dynamic animal studies are needed where 
biomaterial wear particles are injected into the circulation to determine the outcome of 
the particles as well as what effect they may have on the inflammatory process.  
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IN VIVO RESPONSE TO THE INJECTION OF BIOMATERIAL WEAR DEBRIS  
 
 
Abstract 
 
 Total joint replacements fail at a finite rate and the resultant wear debris leads to a 
local inflammatory response that has been well characterized.  The wear debris generated 
by total joint replacements as well as by other biomaterials travels throughout the body to 
the end organs and lymph nodes, yet very little is information is available on the long-
term effect of the particles.  The purpose of this study was to develop an in vivo model 
using the rat tail vein to assess the trajectory of metallic particles and to determine the 
systemic effect of these particles on intracellular adhesion molecule-1 (sICAM-1) 
activation. 
 Stainless steel and commercially pure titanium particles (1 x 108 / 24 hours) were 
injected into the tail vein of the rat and sICAM-1 was measured at 24 hours (after one 
injection) and at 96 hours (after four injections).  Saline injections were used as controls 
and lipopolysaccharide (LPS) was used at the positive control.  Histology was performed 
on the spleens, kidneys and hearts of all animals in the 96 hour group to assess the 
trajectory of the injected particles.  Particles were observed in the spleens of all animals 
using light microscopy and the composition of the particles was confirmed using energy 
dispersive x-ray.  Particles were also found in some of the kidneys and hearts, indicating 
that the particles migrated through the circulatory system.  Finally, at 24 hours, there 
were no significant differences between the stainless steel, titanium or control groups but 
the LPS group was significantly higher.  At 96 hours total exposure, the stainless steel 
group had sICAM-1 values significantly greater than both the titanium and the control 
groups while LPS was significantly higher than all groups.   
The results from this study suggest that if biomaterial wear particles enter the 
circulatory system, they will be distributed to end organs and an increased systemic 
inflammatory state may exist.  As one of the common mechanisms in the pathogenesis of 
osteoporosis and vascular diseases is chronic inflammation, could the proinflammatory 
state created by the systemic distribution of biomaterial wear particles predispose patients 
to diseases that are exacerbated by a proinflammatory state?  Further studies are needed 
to try and address this question. 
 
Introduction 
 Worldwide, approximately 1 million total joint replacements are performed each year 
with the majority being total hip replacements (Ingham and Fisher, 2005).  However, 
long-term studies of total hip replacement have shown a finite failure rate that increases 
with time (Harris, 1995).  The most frequent type of failure is aseptic loosening due to 
osteolysis, a direct result of wear of the prostheses (Harris, 1995; Archibeck et al., 2000).  
As polyethylene and metallic wear particles are generated, they enter the periprosthetic 
tissues and are phagocytized by macrophages, resulting in a local inflammatory response 
(Jacobs et al., 2006; Ingham and Fisher, 2005; Nasser et al., 1989; Nasser et al., 1990).   
 While there is a plethora of data describing the local impact of wear debris from total 
joint replacements, much less is known about the systemic distribution of wear particles 
and what effect, if any, they may have on the inflammatory system.  Indeed, there is 
evidence that wear particles generated in vivo are disseminated away from the implant 
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site.  Particles with optical properties similar to polyethylene have been found in regional 
lymph nodes of patients with total hip replacements, suggesting lymphatic transport 
(Shea et al., 1996).  In addition, several studies have found elevated levels of metallic 
elements, same as those that used to make orthopaedic implants, in distant organs and 
body fluids of patients with total joint replacements (Bartolozzi and Black, 1985; 
Harmsen et al., 1985; Jacobs et al., 1991; Jacobs et al., 1995; Jacobs et al., 1996; Kreibich 
et al., 1996; Jacobs et al., 1998; Jacobs et al., 1999; Urban et al., 2004).  The largest study 
analyzing the systemic distribution of wear particles was conducted by Urban and 
colleagues (2000).  This study showed that the dissemination of wear particles, both 
metallic and polyethylene, to the liver, spleen, or abdominal lymph nodes is a common 
occurrence in patients with a total hip or knee replacement.. It is also important to 
consider that total joint replacements are not the only potential source of wear particle 
generation.  Metallic debris has also been found in the paraspinal soft tissues of patients 
with titanium spinal implants (Wang et al., 1999).  It was determined that the wear debris 
was generated by pedicle screw constructs and deposited in the soft tissue surrounding 
the implant.  Another potential source of wear particle generation is aortic stent grafts.  
Jacobs and colleagues (2003) evaluated the mechanical failure of prosthetic human aortic 
stent grafts over a ten-year period.  A total of six hundred eight-six endovascular stent 
grafts were used to treat patients with aortic aneurysms and sixty patients were identified 
with device fatigue.  Of the sixty failures, forty-three had metallic stent fractures, 
fourteen had suture disruptions and three had holes in the grafts.  Interestingly, these 
material failures occurred within seven distinct stent graft designs and the mean time to 
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failure was nineteen months.  According to Jacobs, the clinical significance of stent graft 
material failure remains uncertain.  However, if the material is released, it may have 
some effect on the local vasculature or it may be transported to other sites in the body and 
may invoke an inflammatory response.
 While the above studies demonstrate the presence of biomaterial wear debris in the 
liver, spleen, and lymph nodes of patients with failed prostheses, the mechanism of 
transport has not been clearly elucidated and may be a combination of several factors.  
Urban and colleagues (2000) suggested that lymphatic transport was the major route for 
dissemination of wear debris in the liver and spleen.  In a previous study, Harmsen and 
coworkers (1985) also hypothesized that particles may have traveled through perivascular 
lymph channels as free particles or as phagocytized particles within macrophages.  For 
those patients who had extensive dissemination of debris, particles were also found in the 
fixed macrophages of Kupffer cells lining the hepatic sinusoids, suggesting the possibility 
of hematogenous dissemination as well as lymphatic (Urban et al., 2000).  Al-Saffar and 
colleagues (1995) also suggested that the presence of metal wear debris in the serum of 
patients with failed prostheses would be the result of the release of debris-containing 
phagocytes into the circulation. 
 Particles may also be transported to and found in sites that have not been previously 
studied.  It has been hypothesized that particles may be transported to remote bone 
marrow by circulating monocytes or by entry of small particles directly into the 
bloodstream (Engh et al., 1997).  Additionally, Simonian and Robinson (1995) have 
reported that titanium wear debris was found in blood that was cycled through an 
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interoperative blood-conservation system used during revision of a THR.  This finding 
may also indicate that microscopic metallic particles may be directly infused into the 
bloodstream. 
 The local inflammatory response to wear particles has been well documented.  
Briefly, after the ingestion of particles, the macrophages then release a variety of 
proinflammatory factors that eventually leads to the activation of osteoclasts and 
loosening of the prosthesis.  These factors include numerous cytokines, chemokines, 
prostanoids, superoxide anions, nitric oxide metabolites, lysosomal enzymes, 
metalloproteinases, and adhesion molecules (Al-Saffar et al., 1995; Boynton et al., 1995; 
Chiba et al., 1994; Goodman et al., 1989; Goodman et al., 1997; Goodman et al., 1996; 
Horikoshi et al., 1994; Ishiguro et al., 1996; Jiranek et al., 1993; Kim et al., 1994; 
Konttinen et al., 1997; Ohlin et al., 1990; Sabokbar and Rushton, 1995; Santavirta et al., 
1993; Takagi et al., 1994; Takagi et al., 1994; Takagi et al., 1995; Takagi et al., 1995; 
Watkins et al., 1997; Xu et al., 1996; Xu et al., 1997).  Of particular interest to this study 
was the identification of cytokines released from macrophages and the upregulation of 
adhesion molecules. 
 Cytokines are short-lived proteins that have effects at extremely low concentrations 
and act locally to modulate numerous cellular processes including growth, differentiation, 
and maturation of cells (Goodman et al., 1998).  The cytokines that have been identified 
in periprosthetic tissues include: IL-1β, IL-6, TNF-α, IL-8, IL-11, and TGF-β (Xu et al., 
1996; Kim et al., 1993; Sabokbar and Rushton, 1995; Al-Saffar et al., 1995).  The data 
suggest that all of the above cytokines are derived from particle-activated macrophages 
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and contribute to the inflammation response by activation of endothelial cells (Al-Saffar 
et al., 1994; Al-Saffar et al., 1995).  Interestingly, some of these same cytokines (IL-6, 
TNF-α, IL-1β) play a central role in mediating cellular and physiological responses in 
age-related diseases such as atherosclerosis, osteoporosis, peripheral vascular disease, 
coronary artery disease, Type 2 diabetes, dementia, Alzheimer’s disease and in some 
forms of arthritis and cancer (Omoigui, 2007).    
 The activation of endothelial cells and the expression of adhesion molecules related to 
wear debris have been demonstrated in three studies.  Sabokbar and Rushton (1995) 
analyzed joint fluid of patients undergoing primary total hip replacement and compared 
the results to those patients who had a loose hip prosthesis.  Significantly elevated levels 
of PGE2, IL-6, IL-8 and adhesion molecules (soluble intercellular adhesion molecule, 
soluble vascular adhesion molecule, and soluble endothelial leukocyte adhesion 
molecule) were found in the fluid from those who had loose hip prostheses.  Additionally, 
Al-Saffar and coworkers (1995) characterized the cellular interactions and the 
mechanisms involved in the recruitment of inflammatory macrophages to the bone 
implant interface in patients with aseptically loosened prostheses.  This study described 
the induction and upregulation of three types of adhesion molecules in the bone-implant 
interface: endothelial leukocyte adhesion molecule-1 (E-selectin); intercellular adhesion 
molecule-1 (ICAM-1); and vascular cell adhesion molecule-1 (VCAM-1).  The level of 
expression of adhesion molecules in the failed tissues was comparable to the levels found 
in inflammatory joint conditions.  Al-Saffar and colleagues postulated that the increased 
expression of the three adhesion molecules was mediated by the local production of IL-1 
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and TNF-α in the failed tissues.  The last study evaluated the response of capillaries and 
postcapillary venules of striated muscle to submicron particles of stainless steel or 
commercially pure titanium (Kraft et al., 2001).  The results from this study indicated that 
wear particles led to the activation of leukocytes with a notable increase in the leukocyte 
endothelial-cell interaction within the first 120 minutes and peaked from the 8-24 hour 
range.  Stainless steel particles elicited a greater response than did the titanium particles, 
with a far more negative effect on virtually all microcirculatory parameters.  The authors 
concluded that not only does wear debris induce a chronic biological reaction but also a 
marked acute tissue response with significant effects to the microcirculation (Kraft et al., 
2001). 
 As discussed above, several studies have found a local activation of adhesion 
molecules around failed implants as a result of the release of inflammatory cytokines.  
However, very little is known about what effect wear particles may have systemically if 
they travel throughout the body.  One question that has not been addressed is if wear 
debris travels through the circulation, can phagocytosis of this debris by macrophages 
lead to a systemic proinflammatory state that may predispose patients to age-related 
diseases?  For example, it is now recognized that atherosclerosis is an inflammation-
mediated disease driven by complex interactions between leukocytes, platelets and cells 
of the vessel wall (Omoigui, 2007).    
 Thus, the purpose of this study was to develop an in vivo model using the rat tail vein 
to assess the trajectory of metallic particles and to determine the systemic effect of these 
particles on the adhesion molecule (ICAM) activation.  It is hypothesized that systemic 
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distribution of biomaterial wear debris will lead to an increased inflammatory response 
measured by vascular endothelium activation.   
 
Materials and Methods 
The first step in this research endeavor was to identify the types of materials to be 
tested and to properly characterize these materials.  Once characterized, particles of the 
chosen materials were tested in vivo by injecting the particles into the tail vein of the rat.  
Histology was performed to determine the fate of the particles and the effect of the 
particles on the inflammatory system was determined by measuring ICAM.   
 
Material Selection and Characterization 
 The materials chosen for this study were 316L stainless steel particles (SS, Ultra Fine 
Technology, Inc., Woonsocket, RI) and commercially pure titanium particles (cpTi, 
Aldrich Chemical Company, Inc., Milwaukee, WI).  These materials were chosen due to 
their extensive use as biomaterials in orthopaedic surgery, facial reconstruction and 
vascular surgery, to name a few.  Particles were chosen based on the sizes of wear debris 
retrieved from periprosthetic tissues of failed implants.  Savio and colleagues (1994) 
reviewed the literature and found that metallic particles from retrieved tissues varied from 
0.1 to 400 microns, with the majority of the reported sizes being less than 3 microns.  The 
manufacturer reported size range for SS particles was less than 5 microns and cpTi was 
1-3 microns.  Prior to use, the particles were sterilized but were not cleansed to remove 
endotoxin due to the fact that lipopolysaccharide and endotoxin-like molecules may 
adhere to the implants themselves during the manufacturing process (Ragab et al., 1999) 
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and thus removal would not represent real world use.  Additionally, systemic endotoxin 
has been hypothesized to bind to wear particles after they are generated in patients (Xing 
et al., 2006).  Finally, Tatro and colleagues (2007) demonstrated that endotoxin 
accumulates on both titanium and polyethylene particles following implantation of 
“endotoxin-free” particles, but is cleared from particles that initially carry high levels of 
adherent endotoxin, suggesting a balance between accumulation and clearance of 
endotoxin level in vivo. 
 In order to determine the size of particles for each type of material, the particles were 
analyzed by an AccuSizer™ 770 Optical Particle Sizer (NICOMP Particle Sizing 
Systems, Inc., Santa Barbara, CA).  Scanning electron microscopy (SEM, S3400N, 
Hitachi) was used to characterize the morphology and energy dispersive X-ray 
spectroscopy (EDX) verified the elemental composition of the particles. 
 
Animal model 
 Adult, male Sprague Dawley rats weighing between 285-300 grams (Charles River 
Breeding Labs, Wilmington, MA) were utilized in this study.  The animals were allowed 
to acclimate two weeks before the study began and were kept on standard pellet food and 
water ad lib.  The Clemson University Institutional Animal Care and Use Committee 
(IACUC) approved this study. 
 
Experimental Groups 
 Two different time points were evaluated in this study: 24 hours post-injection and 96 
hours post-first injection.  For each time point, animals were randomly assigned to the 
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following four groups: saline only (control), cpTi particles (with saline vehicle), SS 
particles (with saline vehicle), and lipopolysaccharide (LPS, positive control, Sigma, St. 
Louis, MO). 
 
Particle Injection 
 The animals were anesthetized with 3% isoflurane through an inhalant mask.  After 
adequate sedation, titanium and stainless steel particles (1 x 108 particles/0.5 cc saline), 
saline only (0.5 cc), and LPS (1 mg/kg plus saline for total volume of 0.5 cc) were 
injected into the tail vein of the rat.  Care was taken to make sure the particles were 
distributed throughout the syringe prior to injection and the diameter of the needle was 
larger than the size of the particles.   
 For the 24 hour test group, the animals received one dose of the different treatments 
and then were sacrificed 24 hours later.  Prior to sacrifice, the animals were sedated with 
3% inhaled isoflurane, and blood was collected via a heart stick.  The blood was allowed 
to clot, centrifuged and the serum was collected and frozen at -20ºC for future ELISA 
analysis.  The following tissues were collected for histological analysis and stored in 10% 
formalin: heart, lungs, kidneys, liver and spleen.  For the 96 hour test group, animals 
received four doses of the different treatments, one dose at baseline and then one dose 
every 24 hours for a total of four doses, and were then sacrificed at 96 hours post the first 
injection. 
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Tissue Analysis 
 Samples of heart, kidney and spleen from the animals treated for 96 hours were 
processed in a tissue processor, embedded in paraffin and sectioned.  One set of slides 
was stained with hematoxylin and eosin (H&E) and another set was prepared unstained.  
The H&E stained slides were examined with light microscopy for the presence of 
metallic particles.  The second set of slides was analyzed via energy dispersive x-ray 
(EDX) to confirm the presence or absence of metallic particles within the samples. 
 
sICAM-1 assay 
 Levels of rat soluble intercellular adhesion molecule-1 (sICAM-1) concentrations 
were measured using a commercially available ELISA kit (Quantikine®, R&D Systems, 
Minneapolis, MN).  Briefly, a specific monoclonal antibody for rat sICAM-1 was pre-
coated onto a microplate to which standards, controls, and samples were pipetted into the 
wells.  If rat sICAM-1 was present, it was bound by the immobilized antibody.  A wash 
removed any unbound substances, and an enzyme-linked polyclonal antibody specific for 
rat sICAM-1 was added to the wells.  After another wash, a substrate solution was added 
to the wells.  The intensity of the color measured is in proportion to the amount of 
sICAM-1 bound in the initial step.   At the time of testing, the serum was thawed at room 
temperature and tests were run in triplicate for expression of the adhesion molecule 
ICAM-1 as directed in the kit instructions with a 50-fold dilution.   
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Statistical Analysis 
 Analysis of variance (ANOVA) was used to test for differences in median sICAM-1 
values using SigmaStat Version 3.5 (Systat Software Inc., Richmond, CA).  If the overall 
p-value from the F-test was significant, then multiple comparisons were made using 
Student-Newman-Keuls Method.  P-values < 0.05 were considered indicative of 
statistical significance.   
 
Results 
Material Characterization 
 A particle size analyzer was used to determine the size, size range and number of 
particles in a known mass of material (Model 770 AccuSizer, Particle Sizing Systems, 
Inc., Santa Barbara, CA).  The mean diameter and standard deviation of the cpTi particles 
was 2.09 μm ± 2.16 μm and 35% of the particles were less than 1 μm.  Also, 99% of 
these particles were less than 10.55 μm.  In an 8.8 mg sample of cpTi, the analyzer 
determined that there were 1.24 x 108 particles.  Finally, the mean diameter and standard 
deviation of the 316L SS particles was 2.64 μm ± 1.49 μm.  Ten percent of the SS 
particles were about one micron or less and 99% of the particles were less than 6.70 μm.    
The total number of particles was calculated to be 5.2 x 107 in a 15.4 mg sample of 
stainless steel.  A complete analysis of the test materials can be found in Appendix A. 
 Electron microscopy showed that the SS particles were predominantly spherical in 
shape with a range of particle sizes observed, the majority of particles being less than 
several microns (Figure 2.1a).  The particles were largely independent particles with little 
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or no agglomeration of particles.  EDX confirmed that the particles were indeed 316L 
stainless steel (Figure 2.1b).  The morphology of the cpTi particles was quite different 
than the SS particles.  Whereas the SS particles were spherical, the cpTi particles were 
irregularly shaped and appeared to perhaps be sticking together.  While the majority of 
the particles were several microns, there were some particles that were in the 10-12 
micron range (Figure 2.2a).  EDX also confirmed that the particles were 96% titanium 
(Figure 2.2b). 
 
Histology and EDX Results  
 
 Using light microscopy, dark black particles were observed in the spleens of all 
animals in both the cpTi group as well as the SS group (Figures 2.3 and 2.4, 
respectively).  The presence of cpTi and SS particles in all spleens were confirmed with 
EDX and representative photos are shown in Figures 2.5 and 2.6 and detailed analysis 
can be found in Appendix B and C.  In addition to spleens, samples of both kidney and 
heart were also analyzed from each animal.  Metallic particles were also visualized, via 
light microscopy and confirmed with EDX, in some of the samples of the kidney and in 
some from the heart but not all of them as with the spleens (pictures not shown).  
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Figure 2.1a  Scanning electron microscopy photo of stainless steel particles. 
 
 
 
 
Element Weight% 
      
C  31.51 
Si  0.39 
Cr  12.28 
Fe  45.16 
Ni  8.99 
Mo  1.67 
  
Totals 100.00 
 
 
Figure 2.1b  Energy dispersive x-ray analysis of stainless steel particles. 
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Figure 2.2a  Scanning electron microscopy photo of commercially pure titanium 
particles. 
 
 
 
 
 
Element Weight% Atomic% 
        
C K 3.95 14.09 
Ti K 96.05 85.91 
   
Totals 100.00  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2b  Energy dispersive x-ray analysis of commercially pure titanium particles. 
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Figure 2.3  Representative sample of titanium found in rat spleen stained by 
Hematoxyline & Eosin (x 40x).  The titanium particles are highlighted by the arrows. 
 
 
 
Figure 2.4  Representative sample of stainless steel (SS) found in rat spleen stained by 
Hematoxyline & Eosin (x 40x).  The SS particles are highlighted by the arrows.
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Figure 2.5  Representative sample of titanium found in rat spleen.  The titanium particles 
(highlighted by the arrows) are reflective and were confirmed with EDX (Appendix B). 
 
 
 
 
 
Figure 2.6  Representative sample of stainless steel found in rat spleen.  The stainless 
steel particles (highlighted by the arrows) are reflective and were confirmed with EDX 
(Appendix C). 
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sICAM-1 Results – 24 Hours 
 After 24 hours, the animals that were exposed to LPS, the positive control, exhibited 
the highest sICAM-1 value, which was followed by those animals treated with titanium 
particles, saline only, and stainless steel particles (Table 2.1).  There were no statistical 
differences between those animals treated with titanium and stainless steel particles at the 
end of 24 hours.  This was also the case when comparing those animals treated with the 
metallic particles versus those getting saline injections alone.  However, the LPS treated 
animals exhibited significantly higher sICAM-1 values than those treated with stainless 
steel particles, titanium particles or saline (p<0.05).  The mean sICAM-1 responses are 
depicted graphically in Figure 2.7.   
 
 
Table 2.1  sICAM-1 response for each treatment at 24 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
Treatment Mean ± SEM 
Lipopolysaccharide (LPS) 
(n=5) 
 
55,200 ± 1600 
Commercially pure titanium (cpTi) 
(n=5) 
 
25,250 ± 550 
Control (saline only) 
(n=5) 
 
23,350 ± 650 
316L Stainless Steel (SS) 
(n=5) 
 
22,750 ± 500 
 
 
sICAM-1 Results – 96 Hours 
 After four injections of particles and 96 hours of continuous exposure, LPS treated 
animals still exhibited the highest sICAM-1 response and was significantly higher than 
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the other treatments (p<0.05).  Unlike the data at 24 hours, there were also other 
significant differences between the treatments.  The animals that were treated with 
stainless steel particles had a significantly higher sICAM-1 response than control or than 
those animals treated with titanium particles (p<0.05).  There was no difference in 
sICAM-1 response between the animals treated with titanium particles and the animals 
treated with saline (control).  The mean sICAM-1 responses at 96 hours are given in 
Table 2.2 and depicted graphically in Figure 2.8.  For all treatments, the sICAM-1 
response at 96 hours was significantly higher than the response at 24 hours (p<0.05) and 
is shown in Figure 2.9.   
 
Table 2.2  sICAM-1 response for each treatment at 96 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
Treatment Mean ± SEM 
Lipopolysaccharide (LPS) 
(n=5) 
 
81,850 ± 3000 
Commercially pure titanium (cpTi) 
(n=5) 
 
32,150 ± 900 
Control (saline only) 
(n=5) 
 
29,400 ± 1300 
316L Stainless Steel (SS) 
(n=5) 
 
40,600 ± 1600 
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Figure 2.7  Serum intracellular adhesion molecule-1 (sICAM-1) concentrations for the 
different treatments at 24 hours post-injection.  Saline group was the control.  (*) 
indicates statistical difference from saline, titanium and stainless steel (p<0.05). 
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Figure 2.8  Serum intracellular adhesion molecule-1 (sICAM-1) concentrations for the 
different treatments at 96 hours post-injection.  Saline group was the control.  (*) 
indicates statistical difference from saline, titanium and stainless steel (p<0.05).  (#) 
indicates statistical difference from saline and titanium (p<0.05). 
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Figure 2.9  Serum intracellular adhesion molecule-1 (sICAM-1) concentrations for the 
different treatments comparing 24 hours to 96 hours post-injection.  Saline group was the 
control.  (*) indicates statistical difference from 24 hours to 96 hours for each treatment 
(p<0.05).   
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Discussion 
 At a local site of injury or infection, cytokine activation (specifically IL-6, IL-1, TNF-
α, and interferons) occurs that then triggers a systemic response consisting of 
leukocytosis; increases in glucocorticoid production; increases in erythrocyte 
sedimentation rates, fever, activation of complement and clotting cascades; decreases in 
serum zinc and iron; and an increase in plasma levels of acute phase proteins, C-reactive 
protein (CRP), serum amyloid A, fibrinogen, and other proteins (Heinrich et al., 1990; 
Omoigui, 2007).  Several vascular diseases have been shown to have elevated levels of 
the cytokines involved in the acute phase response, as well as elevated CRP levels, and it 
is now recognized that one of the common mechanisms in the pathogenesis of 
osteoporosis and vascular diseases is chronic inflammation (Demer, 2002; Libby et al., 
2002; Omoigui, 2007).   
 Most of the information available on the inflammatory response from particles 
generated from implants has been from the local response to wear particles from total 
joint replacements, where the ingestion of particulate wear debris leads to cytokine 
activation as described above.  Little is known about the systemic effect of biomaterial 
wear debris on inflammation and whether this debris may lead to a state of chronic 
inflammation.  The purpose of this study was to determine the fate of biomaterial 
particles injected into the tail vein of the rat and measure the systemic inflammatory 
response generated by the injection of these particles.   
 Injected particles of both stainless steel and commercially pure titanium were found 
in the spleens of all animals and in some samples of both the kidney and the heart, 
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confirming that the particles were transported through the circulatory system to end 
organs.  The metallic particles were identified first through light microscopy and 
composition was confirmed with energy dispersive x-ray (EDX).  To the author’s 
knowledge, this is one of the first studies to analyze the fate of biomaterial wear debris 
that was injected directly into the circulatory system.  The secondary objective of the 
study was to measure the inflammatory response, via sICAM-1, across the various groups 
24 hours after the first injection of particles and after four doses of particles, given every 
24 hours, for a total of 96 hours of continuous exposure.  After 24 hours exposure and a 
single injection of particles, the only significant difference within the groups was that the 
LPS group exhibited a significantly higher sICAM-1 response.  However, after four 
injections of particles and 96 hours of exposure, the animals treated with SS particles 
exhibited a higher sICAM-1 response than both the control and the titanium group, but 
were still lower than LPS.  The sICAM-1 responses for all groups were higher after four 
injections and 96 hours of exposure than after a single injection and 24 hours of exposure. 
 The metallic particles chosen for this study are utilized in many different biomaterials 
and are similar in size to those found in the surrounding tissues of failed total joint 
replacements.  Titanium, either commercially pure or as an alloy, is used widely in the 
medical field such as in: joint replacement parts for hip, knee, shoulder, spine, elbow and 
wrist; bone fixation materials such as nails, screws, nuts and plates; dental implants and 
parts for orthodontic surgery and dental prosthetics; heart pacemaker housings and 
artificial heart valves; surgical instruments for heart and eye surgery; and components in 
high-speed blood centrifuges.  Also chosen for this study were stainless steel 316L 
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particles.  Stainless steel 316L is used extensively in biomaterials such as balloon-
expandable stents, intramedullary nails, fixation plates, bone screws, and spinal fixation 
devices, to name a few.  The above two metals were chosen due to their extensive use 
and due to the fact that the size of the particles closely approximated those retrieved from 
failed joints.  Several retrieval studies have shown that the mean size of metallic particles 
from tissues surrounding failed prostheses ranged from submicron to 5 µm (Hanlon et al., 
1992; Langkamer et al., 1992; Maloney et al., 1992; Maloney et al., 1995).  The cpTi 
particles used in this study had a mean diameter of 2.09 µm and the SS particles had a 
mean diameter of 2.64 µm. 
 In order to study the systemic of effect of biomaterial particles on inflammation, the 
particles were injected into the tail vein of the rat.  Retrieval studies from patients with 
failed prostheses have found metallic particles in the liver, spleen, bone marrow and 
lymph nodes (Urban et al., 2000; Case et al., 1994; Langkamer et al., 1992; Engh et al., 
1997; Peoc’h et al., 1996).  The proposed mechanisms of particle transport from 
prostheses are through the lymphatic system as well as through the circulation (Urban et 
al., 2000).  Thus, the first portion of this study was to prove that the particles did indeed 
travel throughout the circulatory system.  As shown in the light microscopy results and 
confirmed by energy dispersive x-ray analysis, particles of both cpTi and SS were found 
in the spleens of all the animals in both groups.  As the filtering system of the body, the 
spleen is one of the most likely destinations for foreign debris.  In addition to the spleen, 
metallic particles were also found in some samples of both the heart and the kidney, 
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demonstrating the particles that were injected into the tail vein were indeed distributed 
throughout the body. 
 Interestingly, after multiple injections of particles for a continuous exposure of 96 
hours, SS particles elicited a greater sICAM-1 response than cpTi.  This may be 
explained by the fact that titanium is a relatively inert material and has excellent 
biocompatibility (Vallés et al., 2006) while constituents of stainless steel, namely 
chromium and nickel, are capable of eliciting greater inflammatory responses (Kraft et 
al., 2001).  Similar to the results of this study, previous microvascular studies have also 
shown that SS particles elicited a greater inflammatory response than titanium particles 
(Kraft et al., 2003; Kraft et al., 2001).   
 Results from this study show that the particulate biomaterial wear debris injected into 
the tail vein of the rat were indeed distributed throughout the body.  Thus, this in vivo 
model may be utilized to study the effect of systemic debris on inflammatory markers.  
Additionally, after four injections and 96 hours of continuous exposure to the metallic 
particles, animals injected with SS particles had a significantly higher sICAM-1 response 
than those exposed to cpTi particles, confirming results from previous studies looking at 
the differences in inflammatory responses from different biomaterials.  Further studies 
are needed to determine the effect of particles on other markers of inflammatory and 
whether agents exist that may prevent the inflammatory response.  
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SYSTEMIC INFLAMMATORY RESPONSE TO  
BIOMATERIAL WEAR DEBRIS 
 
 
Abstract 
 
 Chronic inflammation plays a role in the pathogenesis of several age-related diseases 
including atherosclerosis, cardiovascular diseases, osteoporosis, Type 2 diabetes, 
dementia and Alzheimer’s disease and some forms of arthritis and cancer.  Data suggest 
that having one type of chronic disease may increase the likelihood of developing another 
chronic disease, with many correlations between osteoporosis and atherosclerosis as well 
as rheumatoid arthritis and atherosclerosis.  Thus, preventing or reducing states of 
chronic inflammation may prevent patients from developing chronic diseases such as 
those mentioned above.   
 One potential source of inflammation that may be modifiable is the inflammatory 
response from biomaterial wear particles.  Biomaterials have been used extensively in 
fields such as orthopaedics, vascular surgery, cardiac surgery, facial reconstruction and 
dental surgery.  However, implants may release biomaterial wear particles and these 
particles have been shown to elicit a pro-inflammatory response.  The majority of the 
information available focuses on the local response to particles released from total joint 
replacements resulting in osteolysis.  While it is known that particles released from 
implants may travel through the circulatory system, little is known about what systemic 
effect the particles may have on the inflammatory system.  Since bisphosphonates act on 
osteoclasts, they have been studied as potential agents that may prevent wear particle 
induced osteolysis.  More recent data suggest they may also act on macrophages, leading 
to apoptosis and possibly inhibiting the inflammatory response to particles.  The purpose 
of this study was to utilize an in vivo animal model to assess the effect of injecting 
biomaterial particles into the circulatory system and to characterize the resultant 
inflammatory response 24 hours after one, four and seven injections.  An additional 
objective was to test the efficacy of the bisphosphonate, risedronate (RIS), in inhibiting 
the expected inflammatory response. 
 Stainless steel particles were injected in the tail vein of the rat and histological 
analysis confirmed the distribution of these particles to end organs.  The IL-6 response to 
particle injection was rapid and quite substantial as compared to TNF-α.  Interestingly, 
the IL-6 response declined over time with the lowest response occurring 24 hours after 
the last of seven daily injections.  Treatment with RIS did not appear to inhibit the IL-6 
response to particles.  As mentioned above, the TNF-α response was minimal compared 
to IL-6.  Unlike the IL-6 response, the TNF-α response was greatest 24 hours after the 
first injection and 24 hours after the seventh daily injection of the different treatments and 
lowest 24 hours after four injections.  As with IL-6, the TNF-α response was not inhibited 
by treatment with RIS.   
 The ICAM-1 response followed a pattern similar to TNF-α with the exception being 
that the ICAM-1 response was more substantial.  Unlike the cytokine response, RIS 
appeared to have a beneficial effect in reducing the ICAM-1 response 24 hours after the 
seventh day of particle injection; there was no difference after one or four injections.  At 
all three time points, the particles only group elicited a significantly higher CRP response 
than control and treatment with RIS inhibited this response as soon as 24 hours after the 
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first injection of particles and throughout the study.  Also, 24 hours after the fourth 
consecutive injection of particles and 24 hours after the seventh day of injections, the 
CRP response to the particles plus RIS group was no different than the control group.  
 To the author’s knowledge, this is the first study to analyze the inflammatory 
response following biomaterial particle injections into the circulatory system.  Not only 
was the pro-inflammatory cytokines, IL-6 and TNF-α, activated but also ICAM-1 and 
CRP.  While treatment with risedronate did not inhibit the cytokine response, it did 
inhibit both ICAM-1 (after seven injections of particles and eight days treatment with 
RIS) and CRP (after one particle injection and two days of treatment with RIS).  One 
possible reason no effect was seen on IL-6 and TNF-α may be that research has shown 
that treatment with bisphosphonates may elicit an acute phase response that is due to γδ T 
cells and not macrophages.  Some bisphosphonates, including risedronate, have been 
shown to cause macrophage apoptosis and thus RIS may have inhibited the cytokine 
response from macrophages leading to the significant decrease in ICAM-1 and CRP.  
Having a therapy that can not only prevent and treat bone loss but may also inhibit 
chronic inflammation that may lead to atherosclerosis would be of significant importance.   
 
 
Introduction 
 Inflammation is defined as a localized response with systemic consequences, elicited 
by injury or tissue damage, which helps to destroy, reduce or sequester both the harmful 
agent and the wounded tissue (Vasto et al., 2007).  The local reaction at the site of injury 
or infection leads to an activation of cytokines (IL-6, IL-1, TNF-α and interferons) that 
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triggers a systemic response consisting of leukocytosis; increases in glucocorticoid 
production; increases in erythrocyte sedimentation rates, fever, activation of complement 
and clotting cascades; decreases in serum zinc and iron; and an increase in plasma levels 
of acute phase proteins, C-reactive protein (CRP), serum amyloid A, fibrinogen, and 
other proteins (Omoigui, 2007; Heinrich et al., 1990).   
 In addition to the described localized response that occurs with injury or trauma, there 
is also a chronic low-grade inflammation state that occurs with aging (Payne, 2006; Vasto 
et al., 2007; Chung et al., 2006).  Chronic inflammation appears to be involved in the 
pathogenesis of age-related diseases such as: atherosclerosis, peripheral vascular disease, 
coronary artery disease, osteoporosis, Type 2 diabetes, dementia and Alzheimer’s disease 
and some forms of arthritis and cancer (Omoigui, 2007; Chung et al., 2006; Vasto et al., 
2007; Payne, 2006).  Some of the key contributors to the inflammatory process are the 
age-related upregulation of NF-κB, IL-1β, IL-6, TNF-α, cyclooxygenase-2, adhesion 
molecules and inducible NO synthase (Chung et al., 2006).  Elevated levels of CRP, IL-6 
and TNF-α have been associated with an increased risk of cardiovascular disease 
(Morrow and Ridker, 2000; Cesari et al., 2003).  Also, increased levels of pro-
inflammatory cytokines have also been positively correlated with risk of primary and 
recurrent myocardial infarction and death (Ridker et al., 2000; Ridker et al., 2000).  There 
is also evidence for a possible role of inflammation in Type 2 Diabetes where increased 
levels of CRP and IL-6 predict the development of this disease (Omoigui, 2007).  IL-6 
levels are also higher in inflammatory joint disease (Kotake et al., 1996) and in 
conditions of rapid bone turnover and hypercalcemia as in Paget’s disease and multiple 
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myeloma (Roodman, 1995).  In postmenopausal women, a direct correlation has been 
shown between bone resorption and serum IL-1, IL-6 and TNF-α levels where the 
identified cytokines stimulate osteoclasts (Miyaura et al., 1995).  Cytokines also induce 
the expression of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1) on endothelial cells that leads to the subsequent increased 
adhesion of monocytes and is involved in the pathogenesis of atherosclerosis (Takahashi 
et al., 1996; McFarlane et al., 2004). 
 Chronic inflammation from one disease state, such as those listed previously, may 
also increase a patient’s risk of developing another disease.  For example, patients with 
prolonged rheumatoid arthritis (RA) have a higher incidence of atherosclerosis than 
patients of the same age with more recent disease onset (del Rincón et al., 2006).  The 
additional inflammatory insult by chronic diseases appears to accelerate atherosclerosis 
and its complications and may be an explanation for higher cardiovascular morbidity and 
mortality in these populations (Tsirpanlis, 2005).  There is also emerging evidence of a 
biological link between osteoporosis and atherosclerosis and the correlation has been 
described in more detail elsewhere (Hamerman, 2005; Danilevicius et al, 2007; 
Bevilacqua et al., 2005; Ylitalo, 2002).  In atherosclerosis, inflammatory cytokines, such 
as IL-1, IL-6 and TNF-α, are released by smooth muscle cells, endothelium and 
macrophages.  Cytokines induce the expression of intracellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells that 
leads to the subsequent increased adhesion of monocytes and is involved in the 
pathogenesis of atherosclerosis (Takahashi et al., 1996; McFarlane et al., 2004).  Finally, 
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macrophages and monocytes cause the differentiation of cells in the vessel wall leading 
to calcification (Tintut et al., 2002).  In osteoporosis, inflammatory cytokines lead to the 
activation of osteoclasts and subsequent bone resorption.  Clinically, risk factors for 
vascular disease, such as dyslipidemia, systemic arterial hypertension, diabetes mellitus, 
and hyperhomocystinemia, have been associated with a higher incidence of low-bone 
mineral bone density (Danilevicius et al., 2007).  And, there are many similarities 
between arterial calcification and osteogenesis, including various cells, proteins and 
cytokines that lead to tissue mineralization (McFarlane et al., 2004).   
 Since chronic inflammation is a factor in many diseases, it appears that a chronic 
inflammatory state may increase the risk of developing other diseases over time.  Thus, it 
would be prudent to identify causes of chronic inflammation that have the potential to be 
modifiable so as not to predispose patients to a potential increased risk of developing 
inflammatory mediated diseases.  One potential source of chronic inflammation may 
come from the release of wear particles from biomaterial implants.  Biomaterials have 
been used in numerous areas such as orthopaedics, vascular surgery, cardiac surgery, 
facial reconstruction, and dental surgery.  One of the most common uses of biomaterials 
is in total joint replacements where approximately one million replacements are 
performed each year with the majority being total hip replacements (Ingham and Fisher, 
2005).  However, long-term studies of total hip replacement have shown a finite failure 
rate that increases with time, with the most frequent type of failure being aseptic 
loosening due to osteolysis (Harris, 1995; Archibeck et al., 2000).   
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 As wear particles are generated, they enter the periprosthetic tissues and are 
phagocytized by macrophages.  Macrophage activation in the periprosthetic tissues is 
stimulated by both ultra high molecular weight polyethylene (UHMWPE) and metallic 
particles.  The activation of macrophages is the key factor in the development of 
osteolysis (Ingham and Fisher, 2005; Buly et al., 1992; Nasser et al., 1989; Nasser et al., 
1990; Moreau et al., 2007).  After the ingestion of particles, the macrophages then release 
a variety of cytokines and other mediators of inflammation that eventually leads to the 
activation of osteoclasts and loosening of the prosthesis.   
 Some of the cytokines that have been identified in periprosthetic tissues include: IL-
1β, IL-6, TNF-α, IL-8, IL-11, and TGF-β (Xu et al., 1996; Kim et al., 1993; Sabokbar 
and Rushton, 1995; Al-Saffar et al., 1995).  In addition to the above in vivo findings, 
many cell culture experiments have shown that human and animal macrophages release 
IL-1, IL-6, TNF-α and PGE2 in the presence of different wear particles, including: 
polymethylmethacrylate (PMMA), UHMWPE, high density polyethylene (HDPE), 
commercially pure titanium (cpTi), Ti6AL4V (retrieved and fabricated), cobalt 
chromium (retrieved and fabricated) and stainless steel (Murray and Rushton, 1990; 
Westacott et al., 1992; Shanbhag et al., 1995; Algan et al., 1996; Sun et al., 1996; Lee et 
al., 1997; Haynes et al., 1998; Nakashima et al., 1999; Robinson et al., 1999, Xing et al., 
1999; Davis et al., 1993; Glant and Jacobs, 1994; Gonzalez et al., 1996; Horowitz et al., 
1993; Shanbhag et al., 1994). 
 The effect of wear debris on the vascular system could potentially have major 
implications.  The majority of the available data describes the impact of wear particles on 
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the local tissue response.  However, particles are distributed throughout the body and in 
the largest study analyzing the systemic distribution of wear particles, particles were 
found in the liver, spleen, and abdominal lymph nodes in patients with a total hip or knee 
replacement (Urban et al., 2000).  While most of the data focuses on total joint 
replacements, wear particles may also be generated from many types of biomaterials.  
Thus, in addition to the local response in the tissue surrounding the implant there may 
also be a systemic inflammatory response to particles that travel throughout the body. 
 As discussed above, the commonality in many diseases is the elevated levels of pro-
inflammatory cytokines and the macrophage is one of the key cells involved in the 
pathogenesis of atherosclerosis and osteolysis.  Thus, any therapy that can inhibit the 
inflammatory response through inactivation of macrophages may also inhibit foam cell 
formation and accumulation of atherogenic cholesterol in arteries (Bevilacqua et al., 
2005) and prevent periprosthetic bone loss.  One such class of drugs that may have dual 
benefit is the bisphosphonates.  Bisphosphonates are potent inhibitors of osteoclastic 
bone resorption and are used to treat Paget’s disease of bone, metastatic and osteolytic 
bone disease, hypercalcemia of malignancy and osteoporosis (Russell, 2006).  
Bisphosphonates have also been shown to inhibit wear debris mediated bone resorption in 
animal models of osteolysis (Shanbhag et al., 1997; von Knoch et al., 2005; Thadani et 
al., 2002; Millett et al., 2002; Iwase et al., 2002) as well as in humans (Antoniou et al., 
2000).  One of the unique properties of bisphosphonates is that they preferentially bind to 
mineral surfaces in bone and thus are available for uptake by osteoclasts.  The most 
common bisphosphonates utilized today, the nitrogen-containing bisphosphonates, are 
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not metabolized but are inhibitors of the mevalonate pathway, thereby preventing the 
biosynthesis of isoprenoid compounds that are essential for the posttranslational 
modification of small GTP-binding proteins such as rab, rho, and rac (Russell, 2006).   
The inhibition of protein prenylation leads to the loss of osteoclastic activity and the 
induction of apoptosis.  Since osteoclasts and macrophages differentiate from the 
monocyte lineage, it is possible that bisphosphonates not only affect bone metabolism but 
also inflammatory responses (Pietschmann et al., 1998). 
 Indeed, in addition to their primary effect on osteoclasts, bisphosphonates have also 
been shown to have an effect on cells and tissues beyond bone.  According to Russell 
(2006), the effects of bisphosphonates on osteoclast precursors, tumor cells, macrophages 
and γδ T cells are most likely explained by sufficient amounts of bisphosphonates 
entering cells to inhibit the mevalonate pathway.  While their effect on osteoclasts has 
been studied extensively, much less is known about the effects of bisphosphonates on 
macrophages.  Macrophages are sensitive to bisphosphonates and are suppressed at 
concentrations much lower than would cause cytotoxicity (Stevenson and Stevenson, 
1986; Mönkkönen et al,, 1994).  More recently, Moreau and colleagues (2007) have 
shown that at low doses the bisphosphonates, risedronate and zoledronate induce 
apoptosis of macrophages in the mouse macrophage-like J774.1 cell line.  This is an 
important observation since bisphosphonates, when given orally, have poor intestinal 
absorption (< 1%).  Additionally, bisphosphonates have also been shown to inhibit TNF-
α release from macrophages exposed to UHMWPE (Huk et al., 2003; Petit et al., 2006) 
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but no effect was seen in macrophages exposed to alumina ceramic (Petit et al., 2006), 
suggesting that the type of particle may play a role.   
 Interestingly, bisphosphonates have also been studied for the prevention or treatment 
of atherosclerosis.  While bisphosphonates predominantly attach to bone, they also 
accumulate in human arterial walls (Lantto et al., 1989; Mori et al., 1992; Ikehira et al., 
1999) and in healthy and atherosclerotic rat aortas (Ylitalo et al., 1996).  From as early as 
the mid-1970’s, bisphosphonates at higher doses were shown to inhibit animal 
experimental atherosclerosis without affecting serum cholesterol or lipid profiles 
(Rosenblum et al., 1975; Kramsch and Chan, 1978; Kramsch et al., 1981; Ylitalo et al., 
1994; Zhu et al., 1994).  More recently, a bisphosphonate at clinical doses has been 
shown to inhibit the intima-media thickening of the carotid artery in humans with type 2 
diabetes being treated for osteopenia (Koshiyama et al., 2000).  The mechanism by which 
bisphosphonates interfere with atherosclerosis may be multi-factorial but one of the key 
events may be macrophage apoptosis by inhibiting intracellular enzymes in the 
cholesterol biosynthesis pathway.  Arterial macrophages play a key role in atherogenesis 
as they ingest modified oxidized low density lipoprotein (LDL) and are then transformed 
to atherogenic foam cells; thus, a therapy that inactivates macrophages may inhibit foam 
cell formation and accumulation of atherogenic cholesterol in the arteries (Bevilacqua et 
al., 2005; Raines and Ross, 1997).   
 As discussed above, many chronic diseases are caused by inflammation and may feed 
upon one another.  One potential source of additional chronic inflammation is 
periprosthetic osteolysis as a result of biomaterial wear debris.  The majority of research 
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published by others has focused on the macrophage mediated local inflammatory 
response around failed total joint replacements; however, very little is known about the 
effect of systemic distribution of wear debris.  The purpose of this study was to utilize an 
in vivo animal model to assess the effect of injecting biomaterial particles into the 
circulatory system and to characterize the resultant inflammatory response.  An additional 
objective was to test the efficacy of a bisphosphonate in inhibiting the response.  It is 
hypothesized that systemic distribution of biomaterial wear debris will lead to an 
increased inflammatory response and that the bisphosphonate will inhibit the response. 
 
Materials and Methods 
The first step in this research endeavor was to select the type of material to be tested 
and to properly characterize the material.  Once characterized, the in vivo inflammatory 
response was determined by injecting the particles into the tail vein of the rat.  The ability 
of the bisphosphonate, risedronate, to inhibit the expected inflammatory response was 
also measured.  Histology was performed to determine the fate of the particles and the 
effect of the particles on the inflammatory system was determined by measuring 
Interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), intracellular adhesion 
molecule-1 (ICAM-1) and C-reactive Protein (CRP). 
 
Material Selection and Characterization 
 The material chosen for this study was 316L stainless steel particles (SS, Ultra Fine 
Technology, Inc., Woonsocket, RI).  This material was chosen due to its extensive use as 
a biomaterial in orthopaedic surgery, facial reconstruction and vascular surgery, to name 
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a few.  Additionally, SS particles were shown to elicit a greater sICAM-1 response than 
commercially pure titanium particles in a previous study as part of this research study.  
Particles were chosen based on the sizes of wear debris retrieved from periprosthetic 
tissues of failed implants.  Savio and colleagues (1994) reviewed the literature and found 
that metallic particles from retrieved tissues varied from 0.1 to 400 microns, with the 
majority of the reported sizes being less than 3 microns.  The manufacturer reported size 
range for SS particles was less than 5 microns.  Prior to use, the particles were sterilized 
but were not cleansed to remove endotoxin due to the fact that lipopolysaccharide and 
endotoxin-like molecules may adhere to the implants themselves during the 
manufacturing process (Ragab et al., 1999) and thus removal would not represent real 
world use.  Additionally, systemic endotoxin has been hypothesized to bind to wear 
particles after they are generated in patients (Xing et al., 2006).  Finally, Tatro and 
colleagues (2007) demonstrated that endotoxin accumulates on both titanium and 
polyethylene particles following implantation of “endotoxin-free” particles, but is cleared 
from particles that initially carry high levels of adherent endotoxin, suggesting a balance 
between accumulation and clearance of endotoxin level in vivo. 
 In order to determine the size of the particles, the particles were analyzed by an 
AccuSizer™ 770 Optical Particle Sizer (NICOMP Particle Sizing Systems, Inc., Santa 
Barbara, CA).  Scanning electron microscopy (SEM, S3400N, Hitachi) was used to 
characterize the morphology and energy dispersive X-ray spectroscopy (EDX) verified 
the elemental composition of the particles. 
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Animal model 
 Adult, male Sprague Dawley rats weighing between 285-300 grams (Charles River 
Breeding Labs, Wilmington, MA) were utilized in this study.  The animals were allowed 
to acclimate two weeks before the study began and were kept on standard pellet food and 
water ad lib.  The Clemson University Institutional Animal Care and Use Committee 
(IACUC) approved this study. 
 
Experimental Groups 
 Animals were randomly assigned to the following four groups: no treatment (control), 
SS particles only (with saline vehicle), SS particles plus lipopolysaccharide (LPS, 
positive control, Sigma, St. Louis, MO) and SS particles plus risedronate (RIS) treatment.  
The three groups receiving particle injections were evaluated at three different time 
points: 24 hours after the first injection (for a total of one injection of particles), 96 hours 
post-first injection (for a total of four injections of particles, one injection per day) and 
168 hours post-first injection (for a total of seven injections of particles, one injection per 
day). 
 
Bisphosphonate Selection 
 Risedronate (Actonel®, Procter & Gamble Pharmaceuticals, Cincinnati, OH), a 
nitrogen-containing bisphosphonate, was evaluated in this study as a potential inhibitor of 
cytokine activation, C-reactive protein and adhesion molecule activation.  Risedronate is 
FDA approved for the treatment and prevention of postmenopausal osteoporosis.  The 
dose used for this study was 5 µg/kg which is a body weight equivalent to the FDA 
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approved human dose.  Also, since this was a short-term study, a loading dose was given 
24 hours prior to the start of injections. 
 
Particle Injection 
 The animals were anesthetized with 3% isoflurane through an inhalant mask.  After 
adequate sedation, stainless steel particles (1 x 108 particles/0.5 cc saline), particles plus 
LPS (1 x 108 particles/0.2 cc saline plus 1 mg/kg LPS for total volume of 0.5 cc) and 
particles plus RIS (1 x 108 particles/0.5 cc saline) were injected into the tail vein of the rat 
(n=6 animals per group).  The dose of particles (1 x 108) was chosen because this dose 
has been shown to elicit inflammatory responses in previous studies (Goodman et al., 
1996; Kim et al., 1998).  The animals receiving risedronate were given an initial 
subcutaneous dose of 5 μg/kg 24 hours prior to the first injection of particles and every 
24 hours thereafter.  Additionally, the particles were vortexed to make sure the particles 
were distributed throughout the syringe prior to injection and the diameter of the needle 
was larger than the size of the particles.   
 For the twenty-four hour test group, the animals received one dose of the different 
treatments and then were sacrificed twenty-four hours later.  Prior to sacrifice, the 
animals were sedated with 3% inhaled isoflurane, and blood was collected via a heart 
stick.  The blood was allowed to clot, centrifuged and the serum was collected and frozen 
at -20ºC for future ELISA analysis.  The following tissues were collected for histological 
analysis and stored in 10% formalin: heart, spleen, aorta plus iliacs and lymph nodes.  For 
the 96 hour test group, animals received four doses of the different treatments, one dose 
at baseline and then one dose every 24 hours for a total of four doses, and were then 
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sacrificed at 96 hours post the first injection.  Finally, the 168 hour test group received 
one dose of the different treatments every day for seven days for a total cumulative 
exposure of 168 hours.  As mentioned previously, the animals receiving risedronate were 
given an initial subcutaneous dose of 5 μg/kg 24 hours prior to the first injection of 
particles and every 24 hours thereafter, depending on the length of the study.   
 
Tissue Analysis 
 Samples of heart, spleen, aorta plus iliacs and lymph nodes from the particles only 
group at 24 and 168 hours were processed in a tissue processor, embedded in paraffin and 
sectioned.  One set of slides was stained with hematoxylin and eosin (H&E) and another 
set was prepared unstained.  The H&E stained slides were examined with light 
microscopy for the presence of metallic particles.   
 
IL-6 assay 
 Levels of rat IL-6 concentrations were measured using a commercially available 
ELISA kit (Quantikine®, R&D Systems, Minneapolis, MN).  IL-6 plays an active role in 
inflammation, immunology, bone metabolism, reproduction, arthritis, neoplasia and 
aging (Omoigui, 2007).  It also contributes to bone resorption and osteoporosis by 
stimulating osteoclast activity.  Briefly, a specific monoclonal antibody for rat IL-6 was 
pre-coated onto a microplate to which standards, controls, and samples were pipetted into 
the wells.  If rat IL-6 was present, it was bound by the immobilized antibody.  A wash 
removed any unbound substances, and an enzyme-linked polyclonal antibody specific for 
rat IL-6 was added to the wells.  After another wash, a substrate solution was added to the 
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wells.  The intensity of the color measured was in proportion to the amount of IL-6 bound 
in the initial step.   At the time of testing, the serum was thawed at room temperature and 
tests were run in triplicate for expression of IL-6 as directed in the kit instructions with a 
2-fold dilution.   
 
TNF-α assay 
 TNF-α also plays a critical role in normal host resistance to infection and as 
mediators of the inflammatory response.  It is produced by activated macrophages as well 
as many other cell types including endothelial cells.  Briefly, a specific monoclonal 
antibody for rat TNF-α was pre-coated onto a microplate to which standards, controls, 
and samples were pipetted into the wells.  If rat TNF-α was present, it was bound by the 
immobilized antibody.  A wash removed any unbound substances, and an enzyme-linked 
polyclonal antibody specific for rat TNF-α was added to the wells.  After another wash, a 
substrate solution was added to the wells.  The intensity of the color measured is in 
proportion to the amount of TNF-α bound in the initial step.   At the time of testing, the 
serum was thawed at room temperature and tests were run in triplicate for expression of 
the adhesion molecule TNF-α as directed in the kit instructions with a 2-fold dilution.  
  
sICAM-1 assay 
 Levels of rat soluble intercellular adhesion molecule-1 (sICAM-1) concentrations 
were measured using a commercially available ELISA kit (Quantikine®, R&D Systems, 
Minneapolis, MN).  Briefly, a specific monoclonal antibody for rat sICAM-1 was pre-
coated onto a microplate to which standards, controls, and samples were pipetted into the 
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wells.  If rat sICAM-1 was present, it was bound by the immobilized antibody.  A wash 
removed any unbound substances, and an enzyme-linked polyclonal antibody specific for 
rat sICAM-1 was added to the wells.  After another wash, a substrate solution was added 
to the wells.  The intensity of the color measured is in proportion to the amount of 
sICAM-1 bound in the initial step.   At the time of testing, the serum was thawed at room 
temperature and tests were run in triplicate for expression of the adhesion molecule 
ICAM-1 as directed in the kit instructions with a 50-fold dilution.   
 
C-Reactive Protein 
 C-Reactive Protein (CRP) was measured utilizing the Rat C-Reactive Protein kit from 
Helica Biosystems Inc. (Fullerton, CA).  This assay was designed for the detection and 
quantification of CRP in rat serum.  CRP is an acute-phase protein produced by the liver 
in conditions of inflammation, bacterial infection, or tissue trauma and is considered to be 
an important acute phase marker in such conditions (Product Insert, Helica Biosystems 
Inc., Fullerton, CA).  Briefly, rat sera were diluted and allowed to react with antibodies 
coated on specially treated microwells.  After incubation, the wells were washed to 
remove unreacted serum proteins, and an enzyme-labeled rabbit anti-rat CRP (conjugate) 
was added to react with and tag the antigen-antibody complexes.  Following another 
incubation period, the wells were washed again to remove unreacted conjugate.  A 
substrate was added to start color development.  The reaction was interrupted with a stop 
solution.  Color intensity (absorbance) was read at a wavelength of 450 nm.  At the time 
of testing, the serum was thawed at room temperature and tests were run in triplicate for 
expression of CRP as directed in the kit instructions with a 4-fold dilution. 
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Statistical Analysis 
 Analysis of variance (ANOVA) was used to test for differences in median IL-6, TNF-
α, sICAM-1 and CRP values using SigmaStat Version 3.5 (Systat Software Inc., 
Richmond, CA).  If the overall p-value from the F-test was significant, then multiple 
comparisons were made using Student-Newman-Keuls Method.  P-values < 0.05 were 
considered indicative of statistical significance.   
 
 
Results 
Material Characterization 
 A particle size analyzer was used to determine the size, size range and number of 
particles in a known mass of material (Model 770 AccuSizer, Particle Sizing Systems, 
Inc., Santa Barbara, CA).  The mean diameter and standard deviation of the 316L SS 
particles was 2.64 μm ± 1.49 μm.  Ten percent of the SS particles were about one micron 
or less and 99% of the particles were less than 6.70 μm.    The total number of particles 
was calculated to be 5.2 x 107 in a 15.4 mg sample of stainless steel.  A complete analysis 
of the test materials can be found in Appendix A. 
 Electron microscopy showed that the SS particles were predominantly spherical in 
shape with a range of particle sizes observed, the majority of particles being less than 
several microns (Figure 3.1a).  The particles were largely independent particles with little 
or no agglomeration of particles.  EDX confirmed that the particles were indeed 316L 
stainless steel (Figure 3.1b). 
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Figure 3.1a  Scanning electron microscopy photo of stainless steel particles. 
 
 
 
 
Element Weight% 
      
C  31.51 
Si  0.39 
Cr  12.28 
Fe  45.16 
Ni  8.99 
Mo  1.67 
  
Totals 100.00 
 
 
Figure 3.1b  Energy dispersive x-ray analysis of stainless steel particles. 
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Histology Results  
 
 After one injection of stainless steel particles, particulate debris was observed in the 
spleens of all six animals.  Particles were observed in the heart in one-third of the 
animals, same as with the lymph nodes and the iliacs and aorta.  These results indicate 
that the particles are indeed distributed throughout the vascular system after one injection 
of particles in the tail vein.  Samples were also analyzed after seven injections of 
particles.  Again, particles were observed in the spleens of all animals.  Two-thirds of the 
animals had particles in the heart and iliacs/aorta tissues while one-third of the animals 
had particles in the lymph nodes. 
 
IL-6 Results 
 24 Hours 
 The mean IL-6 response after 24 hours exposure of the different treatments is 
shown in Table 3.1.  The largest IL-6 response was found in animals treated with 
stainless steel particles plus LPS, followed by particles only, particles plus risedronate 
(RIS) and control.  The three stainless steel groups had IL-6 values that were all 
significantly greater than control (p<0.05), with the particles plus LPS group eliciting 
IL-6 values about 3.5 times control, particles only 2.5 times control and particles plus 
RIS about 2 times control.  The particles plus LPS group was also significantly higher 
than the particles only group and the particles plus RIS group.  There was no 
significant difference between particles only and particles plus RIS.  The results are 
depicted graphically in Figure 3.2. 
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Table 3.1  IL-6 response for each treatment at 24 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
Treatment 
 
Mean ± SEM 
Particles plus LPS 
(n=6) 
 
668 ± 45 
Particles Only 
(n=6) 
 
473 ± 60 
Particles plus Risedronate 
(n=6) 
 
383 ± 18 
Control 
(n=6) 
 
189 ± 18 
 
 
 96 Hours 
 After 96 hours of exposure to the different treatments, the IL-6 response to the 
particles plus LPS, particles only and particles plus RIS groups were all statistically 
larger than the control group (p<0.05).  There were no other differences among the 
groups.  The data are shown in Table 3.2 and graphed in Figure 3.3. 
 
Table 3.2  IL-6 response for each treatment at 96 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
Treatment 
 
Mean ± SEM 
Particles plus LPS 
(n=6) 
 
367 ± 34 
Particles Only 
(n=6) 
 
337 ± 48 
Particles plus Risedronate 
(n=6) 
 
343 ± 29 
Control 
(n=6) 
 
189 ± 18 
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 168 Hours 
 After seven injections or 168 hours of exposure to particles, the particles plus LPS 
group exhibited a significantly higher IL-6 response than the other groups (p<0.05).  
Also, at this time point, the particles plus RIS group was significantly higher than 
both the particles only group and the control group.  There was no difference between 
the particles only group and the control group.  The data are shown in Table 3.3 and 
graphed in Figure 3.4.   
 
Table 3.3  IL-6 response for each treatment at 168 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
Treatment 
 
Mean ± SEM 
Particles plus LPS 
(n=6) 
 
278 ± 17 
Particles Only 
(n=6) 
 
209 ± 9 
Particles plus Risedronate 
(n=6) 
 
235 ± 8 
Control 
(n=6) 
 
189 ± 18 
 
 
 Combined Data - All Time Points  
 Data from all three time points are shown in Figure 3.5.  For each active 
treatment, the response at 24 hours was greatest followed by 96 and 168 hours.  The 
time points were all significantly different from each other. 
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Figure 3.2  Mean IL-6 response after 24 hours of treatment exposure.  Control group was 
no treatment.  (*) indicates statistical difference from control (p<0.05).  (#) indicates 
statistical difference from particles only and particles + RIS (risedronate). 
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Figure 3.3  Mean IL-6 response after 96 hours of treatment exposure.  Control group was 
no treatment.  (*) indicates statistical difference from control (p<0.05).  
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Figure 3.4  Mean IL-6 response after 168 hours of treatment exposure.  Control group 
was no treatment.  (*) indicates statistical difference from control (p<0.05).  (#) indicates 
statistical difference from particles only and particles + RIS (risedronate) (p<0.05).  (^) 
indicates statistical difference from particles only (p<0.05). 
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Figure 3.5  Combined data at 24, 96 and 168 hours.  (*) indicates significant difference 
between 24 hours and the other two time points (p<0.05).  (#) indicates significant 
difference between 96 and 168 hours (p<0.05). 
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TNF-α Results 
 
 24 Hours 
 
 The TNF-α response 24 hours after the first particle injection was highest for the 
particles plus LPS group, followed by particles only, control and particles plus RIS.  
The response for the particles plus LPS group was significantly greater than the other 
groups (p<0.05).  Otherwise, there were no other significant differences.  The mean 
TNF-α response can be found in Table 3.4 and is shown graphically in Figure 3.6. 
 
Table 3.4  TNF-α response for each treatment at 24 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
Treatment 
 
Mean ± SEM 
Particles plus LPS 
(n=6) 
 
33 ± 2 
Particles Only 
(n=6) 
 
21 ± 2 
Particles plus Risedronate 
(n=6) 
 
17 ± 1 
Control 
(n=6) 
 
18 ± 1 
 
 
 96 hours 
  
 The TNF-α response at 96 hours of exposure ranked differently than at 24 hours 
(Table 3.5).  After four injections of particles, the TNF-α response in the animals 
treated with particles plus RIS was significantly greater than the animals treated with 
particles plus LPS, particles only or control (p<0.001, p=0.002, p<0.001, 
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respectively).  The TNF-α response to particles only was also significantly higher 
than particles plus LPS and control (p=0.003, p<0.001, respectively).  There was no 
difference between particles plus LPS and control.  These data are shown graphically 
in Figure 3.7. 
 
 
Table 3.5  TNF-α response for each treatment at 96 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
 
Treatment 
 
Mean ± SEM 
Particles plus LPS 
(n=6) 
 
19 ± 1 
Particles Only 
(n=6) 
 
24 ± 1 
Particles plus Risedronate 
(n=6) 
 
29 ± 1 
Control 
(n=6) 
 
18 ± 1 
 
 
 
 168 hours 
  
 The mean TNF-α response at 168 hours is shown in Table 3.6 and graphed in 
Figure 3.8.  The three active treatment groups were all significantly greater than 
control (p<0.001).  There were no other differences between groups.   
 
Combined Data - All Time Points 
 When comparing all time points, in the particles plus LPS group, the response at 
24 and 168 hours was significantly greater than at 96 hours (p<0.05).  For the 
particles only group, the response at 168 hours was significantly higher than at 24 and 
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96 hours (p<0.05).  Lastly, in the particles plus RIS group, the TNF-α response 
increased significantly over time with significant increases found at each time point 
(p<0.05).  These data are shown graphically in Figure 3.9. 
 
 
Table 3.6  TNF-α response for each treatment at 168 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
Treatment 
 
Mean ± SEM 
Particles plus LPS 
(n=6) 
 
36 ± 2 
Particles Only 
(n=6) 
 
30 ± 2 
Particles plus Risedronate 
(n=6) 
 
37 ± 3 
Control 
(n=6) 
 
18 ± 1 
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Figure 3.6  Mean TNF-α response after 24 hours of treatment exposure.  Control group 
was no treatment.  (*) indicates statistical significance from particles only, particles plus 
RIS (risedronate) and control (p<0.05). 
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Figure 3.7  Mean TNF-α response after 96 hours of treatment exposure.  Control group 
was no treatment.  (*) indicates statistical significance from particles plus LPS, particles 
only and control (p<0.001, p=0.002, p<0.001, respectively).  (#) indicates statistical 
difference from particles plus LPS and control (p=0.003 and p<0.001). 
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Figure 3.8  Mean TNF-α response after 196 hours of treatment exposure.  Control group 
was no treatment.  (*) indicates statistical significance from control (p<0.05). 
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Figure 3.9  Combined data at 24, 96 and 168 hours.  (*) indicates statistical difference 
from 96 hours.  (#) indicates statistical difference from 24 and 96 hours.  (^) indicates 
statistical difference between all time points. 
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sICAM-1 Results  
 24 Hours 
 After 24 hours of exposure to the different treatments, particles plus LPS 
exhibited the highest sICAM-1 response, followed by particles plus risedronate (RIS), 
particles only and control (Table 3.7).  The animals treated with particles plus LPS 
had a significantly greater sICAM-1 response than control, particles only or particles 
plus risedronate.  Additionally, the groups treated with particles only and particles 
plus RIS had significantly higher sICAM-1 values than the control group.  Lastly, 
there was no significant difference between particles only and particles plus RIS.  The 
mean sICAM-1 responses are depicted graphically in Figure 3.10. 
 
 
Table 3.7  sICAM-1 response for each treatment at 24 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
Treatment 
 
Mean ± SEM 
Particles plus LPS 
(n=6) 
 
58,402 ± 2050 
Particles Only 
(n=6) 
 
25,884 ± 1400 
Particles plus Risedronate 
(n=6) 
 
26,773 ± 700 
Control 
(n=6) 
 
21,697 ± 650 
 
 
 
 96 Hours 
 
 Similar to the results at 24 hours, the animals treated with particles plus LPS 
exhibited significantly higher sICAM-1 values than the remaining groups (Table 3.8).  
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However, there were no other significant differences found across the groups.  The 
mean sICAM-1 values at 96 hours are shown graphically in Figure 3.11. 
 
 
Table 3.8  sICAM-1 response for each treatment at 96 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
 
Treatment 
 
Mean ± SEM 
Particles plus LPS 
(n=6) 
 
33,244 ± 2000 
Particles Only 
(n=6) 
 
20,760 ± 1200 
Particles plus Risedronate 
(n=6) 
 
21,479 ± 650 
Control 
(n=6) 
 
21,697 ± 650 
 
 
 168 Hours 
 As with the previous two time periods, the particles plus LPS group was 
significantly higher than the other groups (see Table 3.9).  Different from the results 
at 96 hours, the sICAM-1 response to the particles only group was also significantly 
higher than the control group and the particles plus RIS group.  While significantly 
lower than the particles only group, the response to the particles plus RIS group was 
significantly higher than the control group.  The mean sICAM response at 168 hours 
is shown graphically in Figure 3.12. 
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Table 3.9  sICAM-1 response for each treatment at 168 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are pg/mL. 
 
 
 
Treatment 
 
Mean ± SEM 
Particles plus LPS 
(n=6) 
 
43,661 ± 2200 
Particles Only 
(n=6) 
 
31,374 ± 2200 
Particles plus Risedronate 
(n=6) 
 
26,498 ± 1100 
Control 
(n=6) 
 
21,697 ± 650 
 
 
 
 Combined Data - All Time Points 
 In the particles plus LPS groups, the sICAM-1 response at 24 hours was 
significantly higher than 96 or 168 hours and the response at 168 hours was greater 
than at 96 hours.  For the particles only group, the 24 hour response was larger than 
the 96 hour response and the sICAM-1 response at 168 hours was significantly 
greater than the response at both 24 and 168 hours.  Lastly, in the particles plus RIS 
groups, the sICAM-1 response at 24 and 168 hours was greater than at 96 hours.  
There was no difference between 24 and 168 hours.  These data are shown 
graphically in Figure 3.13. 
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Figure 3.10  Mean serum intracellular adhesion molecule-1 (sICAM-1) response after 24 
hours of treatment exposure.  Control group was no treatment. (*) indicates statistical 
difference from control, particles only and particles plus RIS (risedronate) (p<0.05).  (#) 
indicates statistical difference from control (p<0.05).   
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Figure 3.11  Mean serum intracellular adhesion molecule-1 (sICAM-1) response after 96 
hours of treatment exposure.  Control group was no treatment. (*) indicates statistical 
difference from control, particles and particles plus RIS (risedronate) (p<0.05).   
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Figure 3.12  Mean serum intracellular adhesion molecule-1 (sICAM-1) response after 
168 hours of treatment exposure.  Control group was no treatment. (*) indicates statistical 
difference from control, particles only and particles plus RIS (risedronate) (p<0.05).  (#) 
indicates statistical difference from control (p<0.05).  (^) indicates statistical difference 
from particles only (p<0.05). 
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Figure 3.13  Combined data at 24, 96 and 168 hours.  Control group was no treatment. (*) 
indicates statistical difference from 96 and 168 hours (p<0.05).  (#) indicates statistical 
difference from 96 hours (p<0.05).   
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CRP Results 
 
 24 Hours 
 
 After 24 hours of exposure, the highest CRP response to the different treatments 
was found in the particles plus LPS group, followed by particles only, particles plus 
RIS and control (Table 3.10 and Figure 3.14).  The animals treated with particles plus 
LPS exhibited a significantly higher CRP response than control and particles plus RIS 
(p<0.05).  There was no difference between particles plus LPS and particles only.  
The particles only group was also significantly higher than control and particles plus 
RIS.  Lastly, the particles plus RIS group was higher than control.   
 
 
Table 3.10  CRP response for each treatment at 24 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are μg/mL. 
 
 
Treatment Mean ± SEM 
Particles plus LPS 
(n=6) 
 
149 ± 8 
Particles Only 
(n=6) 
 
128 ± 6 
Particles plus Risedronate  
(n=6) 
 
97 ± 10 
Control 
(n=6) 
 
72 ± 8 
 
 
 96 and 168 Hours 
 Similar to the results at 24 hours, the animals treated with particles plus LPS and 
particles only at 96 and 168 hours exhibited a significantly higher CRP response than 
control and particles plus RIS (p<0.05).  There was no difference between particles 
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plus LPS and particles only.  However, whereas there was a significant difference 
between particles plus RIS and controls at 24 hours, at 96 and 168 hours there was no 
difference between these two groups.  The results at 96 hours is presented in Table 
3.11 and shown graphically in Figure 3.15 and the 168 hour data is given in Table 
3.12 and shown in Figure 3.16.  The different treatments plotted as a function of 
treatment exposure are shown in Figure 3.17.  There were no differences across time 
for each treatment group. 
 
 
Table 3.11  CRP response for each treatment at 96 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are μg/mL. 
 
 
Treatment Mean ± SEM 
Particles plus LPS 
(n=6) 
 
149 ± 12 
Particles Only 
(n=6) 
 
120 ± 14 
Particles plus Risedronate 
(n=6) 
 
85 ± 10 
Control 
(n=6) 
 
72 ± 8 
 
 
 
Table 3.12  CRP response for each treatment at 168 hours post-injection.  Data are 
presented as mean ± standard error of mean (SEM).  Units are μg/mL. 
 
Treatment Mean ± SEM 
Particles plus LPS 
(n=6) 
 
131 ± 10 
Particles Only 
(n=6) 
 
116 ± 12 
Particles plus Risedronate 
(n=6) 
 
83 ± 6 
Control 
(n=6) 
 
72 ± 8 
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Figure 3.14  Mean CRP response after 24 hours of treatment exposure.  Control group 
was no treatment.  (*) indicates statistical difference from control and particles plus RIS 
(risedronate) (p<0.05).  (#) indicates statistical difference from control (p<0.05). 
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Figure 3.15  Mean CRP response after 96 hours of treatment exposure.  Control group 
was no treatment.  (*) indicates statistical difference from control and particles plus RIS 
(risedronate) (p<0.05).   
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Figure 3.16  Mean CRP response after 168 hours of treatment exposure.  Control group 
was no treatment.  (*) indicates statistical difference from control and particles plus RIS 
(risedronate) (p<0.05).   
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Figure 3.17  Combined data at 24, 96 and 168 hours.  Control group was no treatment.  
For each treatment, there are no significant differences across time points. 
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Discussion 
 
 Osteoporosis and atherosclerosis are chronic degenerative diseases that are 
responsible for significant morbidity and mortality (Stafford et al., 2004).  Patients with 
osteoporosis frequently display vascular diseases, including atherosclerosis and arterial 
calcification, a phenomenon that has been observed for over one hundred years 
(Hofbauer et al., 2007).  One of the common mechanisms in the pathogenesis of 
osteoporosis and vascular diseases is chronic inflammation (Demer, 2002).  In fact, 
chronic inflammation appears to play a role not just in osteoporosis and vascular diseases 
but also in Type 2 diabetes, dementia, Alzheimer’s disease and some forms of arthritis 
and cancer (Omoigui, 2007; Chung et al., 2006; Vasto et al., 2007; Payne, 2006).  It 
appears that chronic inflammation from one disease state may increase a patient’s risk of 
developing another disease and possible prevention of a pro-inflammatory insult may 
lower one’s risk of developing future diseases. 
 One potential source of chronic inflammation that may be modifiable is the 
inflammatory response to the gradual release of biomaterial wear particles from implants 
such as total joint replacements.  Numerous studies have shown that the local tissue 
response to both polymeric and metallic particles includes the release of pro-
inflammatory cytokines, particularly IL-6 and TNF-α.  These pro-inflammatory 
cytokines can lead to localized osteolysis and subsequent revision of the total joint 
replacement.  However, little is known about the systemic distribution of biomaterial 
particles and what effect these particles may have on chronic inflammation.  In addition 
to particle release from total joint replacements, wear particles may also be generated 
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from implants such as spinal fixation, fracture fixation and stents, to name a few.  The 
purpose of this study was to utilize an in vivo animal model to determine the effect of 
injecting biomaterial particles into the circulatory system and to see if the 
bisphosphonate, risedronate, would inhibit the expected inflammatory response.  
 Due to its extensive use in orthopaedic surgery, facial reconstructive surgery and 
vascular surgery, stainless steel was chosen as the material of interest.  The particles that 
were utilized were determined to be of similar size to that of retrieved particles from the 
surrounding tissues of failed implants (Savio et al., 1994).  Additionally, in an earlier 
phase of this research, it was found that stainless steel particles elicited a greater 
inflammatory response than commercially pure titanium particles.  Histological analysis 
confirmed that after injecting the particles into the tail vein of the rat, that the particles 
were distributed throughout the circulatory system and were predominantly found in the 
spleen of all animals, whether it was 24 hours after one injection or 168 hours after seven 
injections.  In addition to the spleen, particles were also found in some sections from the 
heart, lymph nodes and iliac arteries.  Phagocytic macrophages are found in many organs, 
such as the liver, kidney, lung, spleen, brain and lymph nodes and when carbon particles 
were injected into a mouse and then killed five minutes later, the carbon particles had 
accumulated in the organs rich in mononuclear phagocytes – lungs, liver, spleen and 
areas of the gut wall (Lydyard and Grossi, 1998).  Similar observations were found in this 
study, where the particles were found in organs rich in macrophages. 
 To the author’s knowledge, the inflammatory response to biomaterial particles 
injected into the circulatory system has not been previously evaluated.  In this study, the 
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tumor necrosis factor alpha response (TNF-α) was relatively small.  Previous in vitro 
studies demonstrated elevated levels of TNF-α when macrophages were exposed to 
biomaterial particles for short time periods, usually 24 hours.  However, in this study, the 
response to one injection of particles only into the circulation, for a total of 24 hours 
exposure, did not vary significantly from control.  After four and seven daily injections 
and exposure time of 96 and 168 hours, the TNF-α response was significantly greater 
than control (24 pg/mL versus 18 pg/mL at 96 hours and 30 pg/mL versus 18 pg/mL at 
168 hours, respectively); however the response was still relatively small.  As expected, 
the positive control, the particles plus LPS, exhibited the highest TNF-α response after 24 
hours, however there was a significant decrease in the TNF-α response to the particles 
plus LPS after 96 hours.  This response was not seen with the particles only group or the 
particles plus RIS group where the trend was for the response to increase over exposure 
time.  Perhaps this can be explained as a compensatory response to the LPS.  At 96 hours, 
treatment with particles plus RIS was significantly higher than particles only but at 168 
hours, there was no difference between the two groups.  This TNF-α response to particles 
plus RIS may be explained by the acute phase response that may be seen with the 
nitrogen containing bisphosphonates, such as risedronate.  While the mechanism has not 
been fully elucidated, it seems to be associated with the release of TNF-α and IL-6 
(Schweitzer et al., 1995; Sauty et al., 1996; Thiebaud et al., 1997).  In a further study by 
Hewitt and colleagues (2005), it was shown that nitrogen containing bisphosphonates 
induce rapid and copious production of TNF-α and IL-6 by human peripheral blood γδ T 
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cells and not cells of the monocytic lineage, which is in contrast to the typical acute phase 
response. 
 Unlike the small TNF-α response, the IL-6 response to the different treatments was 
quite substantial, especially at 24 and 96 hours.  At these time points, the IL-6 response 
was significantly greater than control but there was no difference at 168 hours.  
Interestingly, the IL-6 response decreased significantly from 24 to 96 to 168 hours for not 
only the particles only group but for the particles plus LPS and particles plus RIS groups 
as well.  Thus, it appears that the IL-6 response was not dependent of the number of 
particle injections; rather the largest response was seen after only one dose of particles 
and then the response seems to even out with all treatments as the number of injections 
increases.  The particles plus RIS group was significantly higher than control at all time 
points.  The mean IL-6 response for the particles plus RIS group did not vary from the 
particles only group except at 168 hours where the difference was significant.  However, 
unlike the TNF-α response where the values significantly increased over time, the IL-6 
values significantly decreased over time.  The IL-6 response to the particles plus RIS may 
be explained as described above for the TNF-α response, where the acute phase response 
may be dictated by γδ T cells as opposed to cells of the monocyte lineage.  Since the 
proinflammatory response to the particles plus RIS group may not be dependent on the 
ability to suppress the response from the macrophage, it is difficult to ascertain the 
benefit risedronate may have on suppressing particle induced pro-inflammatory cytokine 
response. 
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 In addition to evaluating the effect of different treatments on cytokine response, 
another goal of this study was to characterize the effect of biomaterial particles on 
intracellular adhesion molecule-1 (ICAM-1).  Cytokines induce the expression of 
intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1) on endothelial cells that leads to the subsequent increased adhesion of 
monocytes and is involved in the pathogenesis of atherosclerosis (Takahashi et al., 1996; 
McFarlane et al., 2004).  Thus, it is important to understand what effect biomaterial 
particles may have on the activation of adhesion molecules.  At 24 hours, the particles 
only group as well as the particles plus LPS and particles plus RIS groups exhibited 
significantly higher ICAM-1 values than control.  Similar to what was seen with the 
TNF-α response, there was a significant decrease from 24 hours to 96 hours and then a 
significant increase from 96 hours to 168 hours.  At 96 hours, the only significant 
difference found was that the particles plus LPS was significantly higher than particles 
only, particles plus RIS and control.  At 168 hours, the ICAM-1 response for the particles 
plus LPS group was still significantly greater than all other groups.  The ICAM-1 
response for the particles only and particles plus RIS groups was significantly larger than 
control.  However, the particles plus RIS group was significantly lower than particles 
only.  Based on this result, it is possible that the addition of risedronate inhibited the 
ICAM-1 response caused by particle injection.   
 Lastly, the C-reactive protein (CRP) response to the injected particles was analyzed.  
CRP is synthesized in the liver and it is induced by IL-1 and IL-6 (Ylikorkala et al., 
2003).  Since CRP plays a role in atherosclerosis, it would be interesting to see what 
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effect biomaterial particles have on CRP and if risedronate could inhibit the response.  At 
24 hours, the mean CRP response for all three treatment groups was significantly greater 
than control.  However, at 96 and 168 hours, only the particles plus LPS and particles 
only groups were different from control.  There was no significant difference between the 
particles plus RIS group and control, indicating that at 96 and 168 hours, treatment with 
risedronate inhibited the CRP response seen with particles only.  CRP response did not 
differ across time points; the mean response at 24 hours was similar to both 96 and 168 
hours.  To the author’s knowledge, this is the first time CRP response to biomaterial wear 
particles and the effect of a bisphosphonate to inhibit this response has been evaluated.  
Ylikorkla and colleagues (2003) studied the effects of oral hormone therapy and 
alendronate, given alone or together, on CRP and soluble E-selectin and on sex hormone-
binding globulin levels in osteoporotic elderly women.  They found that the 
bisphosphonate, alendronate, had no effect on vascular markers or sex hormone-binding 
globulin.   
 This is the first study to analyze the effect of injecting biomaterial particles into the 
circulatory system and to characterize the resultant inflammatory response by measuring 
IL-6, TNF-α, ICAM-1 and CRP levels.  Particle injection led to an increase of all 
parameters that varied over the different assessment times.  While treatment with 
risedronate did not inhibit the cytokine response, it did inhibit both the ICAM-1 and CRP 
response by 168 hours and 24 hours, respectively as compared to particles only.  The 
CRP response for the risedronate treated group was the same as control at 96 and 168 
hours.  Thus, based on the results from this study, systemic distribution of biomaterial 
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wear particles causes a significant inflammatory response that may be mediated, at least 
in part, by the concurrent treatment with the bisphosphonate, risedronate, and may 
prevent predisposing patients to the risk of further inflammatory related diseases. 
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CONCLUSIONS 
 
 
Chronic inflammation has been implicated as a contributing factor to many chronic 
diseases, such as vascular diseases and osteoporosis.  Identifying potential causes of 
inflammation and mediating the response may help prevent future diseases.  This study 
was designed to test the hypotheses that biomaterial particles elicit an inflammatory 
response both in vivo and in vitro and that the response can be mediated by treatment 
with the bisphosphonate, risedronate.  In order to test these hypotheses, the study was 
divided into three phases. 
Cell co-culture studies of endothelial cells and macrophages exposed to biomaterial 
particles in a contact and a non-contact configuration were studied in the first phase of 
this project.  In this phase of the study, particles of commercially pure titanium and high 
density polyethylene particles did not elicit a significantly higher inflammatory response 
than cells alone after 24 hours of exposure. And, the addition of risedronate to the cell co-
culture exposed to particles did not significantly inhibit the inflammatory response.  
While there were no significant differences in this study, there were trends to treatment 
effect.  It is possible that 24 hours was not enough time to see a treatment effect in the co-
culture system although in studies by other investigators macrophages alone exposed to 
particles for 24 hours elicited significantly higher pro-inflammatory cytokine levels.  
Also, the amount of particles used in this test scenario has been shown in previous studies 
to elicit a response but it may be possible that the amount of particles used was not high 
enough to elicit a greater response.  Finally, and most likely, a significant effect may have 
been found if the tests had been run more times as there was a trend towards effect.
The second phase of this study was designed to assess the trajectory of biomaterial 
metallic particles after injection into the circulatory system and to determine the effect of 
these particles on intracellular adhesion molecule-1 (ICAM-1).  Particles injected into the 
tail vein of the rat were found in multiple end organs with the primary accumulation 
being in the spleen.  Particle composition was confirmed by energy dispersive x-ray.  
Also, after 96 hours of total exposure to particles (one injection of particles every day for 
four days), stainless steel particles elicited a significantly higher ICAM-1 response than 
commercially pure titanium particles and control (saline only).  To the author’s 
knowledge, this is the first study to analyze the effect of biomaterial particles traveling 
throughout the circulatory system.  Results from this study suggest that as wear particles 
are released from implant surfaces and enter the circulatory system, they will end up in 
end organs with primary filtration at the spleen and depending on the type of particle, 
may elicit a significant inflammatory response.  Most studies have focused only on the 
local response to biomaterial particles, not the systemic effect of the migration of 
particles.   
Lastly, the final phase of this study was aimed at using an in vivo model to assess 
again the trajectory of injected stainless steel particles into the circulatory system and to 
characterize the resultant inflammatory response 24 hours after one, four and seven daily 
injections.  An additional objective was to test the efficacy of the bisphosphonate, 
risedronate, in inhibiting the expected inflammatory response.  Stainless steel particles 
were found in the spleens of all animals and in other organs of some animals after just 
one injection of particles.  Not surprisingly, in the animals that received seven injections, 
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particles were again found in all spleens as well as in the heart and/or iliacs/aorta tissues 
in two-thirds of the animals.   
Particles only injection, particles plus LPS and particles plus risedronate also elicited 
a significant IL-6 response, versus no treatment, after one and four injections of particles.  
After seven injections, there was no difference between particles only and control, but the 
other two groups were still significantly higher than control.  Interestingly, the IL-6 
response was greatest after one injection (or 24 hours of exposure to particles) and 
declined significantly over time.  In contrast to the IL-6 response, the TNF-α response 
was increased over time except for the particles plus LPS response at 96 hours.  
Additionally, the TNF-α response was significantly lower than the IL-6 response.  After 
one injection, only the particles plus LPS group was significantly higher than control.  
However, after four injections, the particles only group and particles plus risedronate 
group was greater than control.  After four injections, the particles plus risedronate was 
significantly higher than particles only but there was no difference between the two 
groups after seven injections.  This increased TNF-α response seen in the particles plus 
risedronate group may be explained by the acute phase response that has been seen with 
the nitrogen containing bisphosphonates, such as risedronate.  While the mechanism of 
the acute phase response is not fully understood, it appears to be associated with the 
release of TNF-α and IL-6.  Also, nitrogen containing bisphosphonates have been shown 
to induce rapid production of TNF-α and IL-6 by human peripheral blood δγ T cells and 
not the cells of the monocytic lineage.  While the addition of risedronate did not 
significantly lower the IL-6 and TNF-α response versus particles only, it is difficult to 
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ascertain whether the pro-inflammatory cytokine response was a result of the biomaterial 
particle distribution or potentially from the acute phase response that has been observed 
with the nitrogen containing bisphosphonates. 
The final phase of this study also analyzed the ICAM-1 and CRP response.  
Cytokines induce the expression of ICAM-1 on endothelial cells which then leads to the 
subsequent increased adhesion of monocytes and involvement in the pathogenesis of 
atherosclerosis.  After one injection, all treatment groups were significantly higher than 
control.  After seven injections, the ICAM-1 response for the particles only and particles 
plus risedronate group was significantly larger than control.  However, the particles plus 
risedronate group was significantly lower than particles only.  Thus, in this study, the 
addition of risedronate appeared to lower the ICAM-1 response as compared to particles 
only after seven injections or 168 hours exposure to particles. 
Lastly, since CRP plays a role in atherosclerosis, it is important to understand what 
effect, if any, biomaterial particles have on this response.  After one injection, all three 
treatment groups were significantly larger than control and the particles plus risedronate 
group was significantly lower than the particles only group.  After four and seven 
injections, there was also no difference between the particles plus risedronate group and 
control while the particles only group was significantly higher than control.  These data 
suggest that risedronate mediated the CRP response seen with injecting particles only.  
Additionally, CRP response did not vary significantly across time points.  To the author’s 
knowledge, this is the first study to analyze the CRP response to biomaterial particles and 
the effect of a bisphosphonate to inhibit the response.   
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In conclusion, this study demonstrated that particles injected into the circulatory 
system of the rat travel throughout the circulatory system and are distributed to end 
organs, predominantly the spleen.  Particles were also found in other organs such as the 
heart and kidney, as well as in the aorta and in lymph nodes, although not as frequently as 
the spleen.  Measurement of pro-inflammatory markers indicated that particle injection 
increases IL-6, TNF-α, ICAM and CRP versus control.  The addition of the 
bisphosphonate, risedronate, did not reduce the cytokine response but did appear to 
inhibit or mediate the ICAM and CRP response.  To the author’s knowledge, this is the 
first study to demonstrate the effect of injected particles into the circulatory system and to 
measure the effect of risedronate to alter the inflammatory response to particle injection. 
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RECOMMENDATIONS 
 
 
1. For future cell culture work, it would of interest to compare bisphosphonate 
potency on macrophages and osteoclasts to see how they compare.  The majority 
of bisphosphonate data focuses on the effect of bisphosphonates to “frustrate” the 
osteoclast and impair its resorptive functions or on apoptosis.  By culturing 
osteoclasts and macrophages and comparing different doses of bisphosphonates, 
additional information would be available to determine if the current FDA 
approved doses of bisphosphonates that suppress osteoclastic activity are 
sufficient to suppress macrophage activity.   
2. The release of wear particles from biomaterials varies significantly depending on 
many factors including the location of the implant in the body and the type of 
implant.  Further understanding of the critical amount of particles needed to cause 
an increase in inflammatory parameters could be achieved by using the 
macrophage-endothelial cell co-culture and treating the culture with varying 
amount of particles.  Additionally, the study could be expanded to include more 
types of particles to determine if the type of particle has an effect on the response.  
3. UHMWPE particles have been shown to be one of the most biologically active 
wear particles in previous studies.  It is recommended that UHMWPE particles be 
added to the in vivo model to assess the effect of this type of particle on 
distribution and the inflammatory response.  Introducing UHMWPE particles into 
the circulatory system introduces a greater challenge than metallic particles as the 
UHWMPE particles clump together.  One potential method would be to introduce 
 the particles with a catheter via a continuous arterial or venous access where the 
particles would be given gradually over time to avoid clumping.  Further 
information would be gained by adding other particles types as well. 
4. In this study, a systemic inflammatory response was demonstrated by measuring 
various inflammatory parameters in the serum collected from the in vivo study.  
To determine a more local effect at various sites including areas that are most 
likely to develop vascular disease, it is recommended that the in vivo study be 
repeated and immunohistochemistry be performed on the tissues to analyze the 
local inflammatory response as opposed to the systemic response.   
5. In this study, risedronate, at an equivalent dose to the FDA approved human dose 
for osteoporosis, was given to the animals subcutaneously to ensure they received 
the full dose of drug as oral bisphosphonates are poorly absorbed.  It would be of 
interest to compare the effectiveness of risedronate when given orally versus 
subcutaneously, since the FDA approved dosing route is oral.  An additional 
parameter to address is how often risedronate could be dosed, i.e., could it be 
given weekly or monthly versus daily.   
6. This study demonstrated a rapid distribution of particles and an inflammatory 
response within the first twenty-fours of exposure.  Since implants are usually in 
the body for a long period of time, it would be interesting to measure the long-
term inflammatory response to particles as well as the distribution profile over 
time.  Thus, it is recommended that the animal study be repeated and the time 
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course increased to six months to one year so that particle accumulation can be 
modeled over time.  This would also provide more information on drug efficacy. 
7. Bisphosphonates have also shown promise in reducing the osteoclastic activity 
following total joint replacement and in instances of wear particle induced 
osteolysis.  While therapy prevents bone loss, a systemic inflammatory response 
is still occurring.  Another method of trying to reduce both osteoclastic activity as 
well as the systemic inflammatory response is to test the ability to coat the 
implant with a bisphosphonate that will be released over time.  This drug delivery 
system would gradually release drug over time and potentially mediate the 
inflammatory response.  
8. This study demonstrated the ability of risedronate to inhibit sICAM-1 and CRP in 
an in vivo model studying the effect of biomaterial particles on the inflammatory 
system.  It is recommended that a porcine animal model of atherosclerosis be 
tested to determine the efficacy of risedronate in inhibiting the progression of this 
disease by modulating these important markers of atherosclerosis.  Additionally, it 
would be interesting to test the ability of risedronate to inhibit restenosis 
following angioplasty and endovascular stenting, specifically using a drug 
delivery system to deliver risedronate to the particular areas of need. 
9. Lastly, in order to fully understand the impact of a chronic inflammatory state 
caused by biomaterial particles on another chronic disease, it is recommended that 
an in vivo study be performed with a porcine animal model of atherosclerosis that 
gets injections of particles over time.  By combining these two phenomena, it will 
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allow researchers to determine if biomaterial particles exacerbate atherosclerosis 
as a function of particle loading and exposure time.  Additionally, it is 
recommended that these animals be treated with risedronate to determine the 
efficacy of the drug to modulate the inflammatory response.  
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APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A 
 
Particle Size Analysis 
 
 
 A complete analysis from the particle size analyzer is given in Appendix A.  These 
analyses include results for the high density polyethylene particles, the 316L stainless 
steel particles and the commercially pure titanium particles.  The first page of the analysis 
contains information such as the number of particles analyzed and the total number of 
particles calculated to be in the sample.  Also, a population distribution chart is shown 
that illustrates the size distribution of particles.  The next page gives a summary of the 
number of particles (percentage) that falls into certain size ranges.  Also given on this 
page is the mean diameter, standard deviation and various other statistical measurements.  
The remaining pages of the analysis show a detailed breakdown of the particles that were 
measured.  
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Appendix B 
Confirmation of Titanium Particles via Energy Dispersive X-ray 
 
 Energy dispersive x-ray was utilized to confirm the presence of metallic particles in 
histology samples as observed with light microscopy.  The below image and analysis is 
representative of the titanium samples analyzed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Element Weight% 
      
C K 41.56 
O K 12.63 
Na K 0.31 
Si K 1.33 
Ca K 0.26 
Ti K 43.90 
  
Totals 100.00 
Appendix C 
Confirmation of 316L Stainless Steel Particles via Energy Dispersive X-ray 
 
 Energy dispersive x-ray was utilized to confirm the presence of metallic particles in 
histology samples as observed with light microscopy.  The below image and analysis is 
representative of the stainless steel samples analyzed. 
 
 
 
 
 
 
 
 
 
 
Element Weight% 
      
C K 24.77 
O K 2.76 
Na K 1.35 
Mg K 0.34 
Si K 4.09 
Ca K 0.71 
Cr K 12.27 
Fe K 44.08 
Ni K 7.99 
Mo L 1.63 
  
Totals 100.00 
 
 
 
 
 
 
 
